CN112047953A - 小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 - Google Patents
小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 Download PDFInfo
- Publication number
- CN112047953A CN112047953A CN201910491707.XA CN201910491707A CN112047953A CN 112047953 A CN112047953 A CN 112047953A CN 201910491707 A CN201910491707 A CN 201910491707A CN 112047953 A CN112047953 A CN 112047953A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- cancer
- cdcl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 96
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- -1 cyanomethyl Chemical group 0.000 claims description 18
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 9
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 6
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 229930182843 D-Lactic acid Natural products 0.000 claims description 3
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010077895 Sarcosine Proteins 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229940022769 d- lactic acid Drugs 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229940071870 hydroiodic acid Drugs 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940116298 l- malic acid Drugs 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 229940033355 lauric acid Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 3
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229960002969 oleic acid Drugs 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 229940116315 oxalic acid Drugs 0.000 claims description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 3
- 229940081066 picolinic acid Drugs 0.000 claims description 3
- 229940043230 sarcosine Drugs 0.000 claims description 3
- 229940000207 selenious acid Drugs 0.000 claims description 3
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 229940005605 valeric acid Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229910052757 nitrogen Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 268
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- 238000003786 synthesis reaction Methods 0.000 description 94
- 230000015572 biosynthetic process Effects 0.000 description 88
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 69
- 238000005160 1H NMR spectroscopy Methods 0.000 description 69
- 239000007787 solid Substances 0.000 description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 28
- 239000011734 sodium Substances 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 239000003208 petroleum Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940125898 compound 5 Drugs 0.000 description 10
- 238000010626 work up procedure Methods 0.000 description 10
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 229940126179 compound 72 Drugs 0.000 description 9
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 9
- 239000002840 nitric oxide donor Substances 0.000 description 9
- 238000010189 synthetic method Methods 0.000 description 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000001308 synthesis method Methods 0.000 description 7
- XFSFVSLECXCYIC-UHFFFAOYSA-N 3-(benzenesulfonyl)-1,2,5-oxadiazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C=1C=NON=1 XFSFVSLECXCYIC-UHFFFAOYSA-N 0.000 description 6
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229940125877 compound 31 Drugs 0.000 description 4
- 229940125900 compound 59 Drugs 0.000 description 4
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- MCMSJVMUSBZUCN-UHFFFAOYSA-N 9,10-dimethoxy-3-methyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2C)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C MCMSJVMUSBZUCN-UHFFFAOYSA-N 0.000 description 3
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 3
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- AMQIPHZFLIDOCB-UHFFFAOYSA-N 3-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC=CC(O)=C1 AMQIPHZFLIDOCB-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- OKVJCVWFVRATSG-UHFFFAOYSA-N 3-hydroxybenzyl alcohol Chemical compound OCC1=CC=CC(O)=C1 OKVJCVWFVRATSG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- JVZZUPJFERSVRN-UHFFFAOYSA-N 2-methyl-2-propylpropane-1,3-diol Chemical compound CCCC(C)(CO)CO JVZZUPJFERSVRN-UHFFFAOYSA-N 0.000 description 1
- MUROMQNYCWNWFJ-UHFFFAOYSA-N 3-Ketone-9beta-Hydroxy-4beta, 11alpha, 13, 15-tetrahydrozaluzanin C Natural products C1C(O)C(=C)C2CC(=O)C(C)C2C2OC(=O)C(C)C21 MUROMQNYCWNWFJ-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical group CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 description 1
- TYYCNSUODPEVQP-UHFFFAOYSA-N 8-[(4-fluorophenyl)sulfonylamino]-4-(3-pyridin-3-ylpropyl)octanoic acid Chemical compound C=1C=CN=CC=1CCCC(CCC(=O)O)CCCCNS(=O)(=O)C1=CC=C(F)C=C1 TYYCNSUODPEVQP-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000266331 Eugenia Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- BWVAOONFBYYRHY-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(CO)C=C1 BWVAOONFBYYRHY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- SKNVIAFTENCNGB-UHFFFAOYSA-N dehydroleucodine Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CC(=O)C2=C1C SKNVIAFTENCNGB-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 229930015714 guaianolide Natural products 0.000 description 1
- 150000004273 guaianolide derivatives Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- JLRMRTRHBRVQMS-UHFFFAOYSA-N hydrogen peroxide;2-methylpropan-2-ol Chemical compound OO.CC(C)(C)O JLRMRTRHBRVQMS-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了式(Ⅰ)所示的小白菊内酯‑苯磺酰基呋咱衍生物及其盐，制备方法及其在制备抗癌药物中的用途。
Description
技术领域
本发明涉及药物化合物，具体提供了一种小白菊内酯-苯磺酰基呋咱衍生物及其盐，并涉及小白菊内酯-苯磺酰基呋咱衍生物及其盐的制备及其在制备抗癌药物中的用途。
背景技术
小白菊内酯(parthenolide)是从木兰科观光木属植物观光木、菊科植物野甘菊中提取分离出来的倍半萜烯内酯化合物，作为草药可能有助于癌症，白血病和偏头痛的治疗。其活性基团C环上的α，β-不饱和内酯，能够选择性的杀死白血病细胞，但是其水溶性、血浆稳定性较差，而且活性也较低，有人研究试图通过对其进行结构修饰来进一步提高其活性、水溶性以及血浆稳定性[Q.Zhang,Y.Lu,etl.Y.Chen,Guaianolide sesquiterpenelactones,a source to discover agents that selectively inhibit acutemyelogenous leukemia stern and progenitor cells,J.Med.Chem.,55(2012)8757-8769.]。近几十年，一氧化氮供体是常被人们用以阐明许多过去未能解释的生理现象，迅速成为近年来研究的热点。一氧化氮自由基是一种寿命较短的自由基，半衰期仅数秒钟，因为其分子小且具有亲脂性，所以很容易透过细胞膜[Huerta S,Chilka S,Bonavida B,Nitricoxide donors:Novel cancer therapeutics(Review).International Journal ofOncology,2008,33(5):909-927.]。一氧化氮在体内由L-精氨酸和氧分子在一氧化氮合酶(NOS)催化下生成。在哺乳动物生理和病理生理反应中发挥着非常重要的作用，如参与维持微血管和大血管的动态平衡、神经信号传导、免疫炎症的调节、肿瘤发生与转移等多种生理病理过程[Thomas D D,Ridnour L A,Isenberg J S,et al,The chemical biology ofnitric oxide:Implications in cellular signaling.Free Radical Biology andMedicine,2008,45(1):18-31；Kiechle F L,Malinski T,Nitric oxide.Biochemistry,pathophysiology,and detection.American Journal of Clinical Pathology,1993,100(5):567-575.]。体内NO缺乏常与多种疾病的形成密切相关，因此外源性NO对于这些疾病的预防和治疗有着重要意义。所以，NO供体药物成为了热门的新型药物研究对象，苯磺酰基呋咱是一种常见的NO供体单元。本发明提供了此类小白菊内酯-苯磺酰呋咱衍生物或其盐的制备，以其为有效成分的治疗癌症或辅助治疗癌症的药物组合物，以及该药物化合物和组合物在制备抗癌或辅助抗癌药物中的应用。
发明内容
本发明提供了式(Ⅰ)所示的小白菊内酯-苯磺酰基呋咱衍生物及其盐，并涉及如式(Ⅰ)所示的小白菊内酯-苯磺酰基呋咱衍生物及其盐在制备抗癌药物中的应用。
如式(Ⅰ)所示的小白菊内酯-苯磺酰基呋咱衍生物，
式(Ⅰ)中X为氧原子或氮原子；
并且R1为如下结构之一：
式(Ⅰ)中，R5可以存在也可以不存在，当R5不存在时，R3、R4共同构成单键；或当R3和R5为氢时，R4为-NR6R7；其中R6和R7可以相同或不同，分别为氢、烷基、环烷基、羟基取代烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基、杂环基、三氟甲基、多氟取代烷基、腈基、腈基甲基、酰基、氨基甲酰基、磺酰基、磺酰胺基或芳氧烷基；R6、R7和N原子形成环状结构。
本发明的另一优选方案是，在上述方案的基础上，R6、R7和N原子形成环状结构为3–9元环，环状结构上可以被一个或多个取代基取代，取代基包括氢、烷基、环烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基或杂环基。
本发明的另一优选方案是，在上述方案的基础上，所述小白菊内酯-苯磺酰基呋咱衍生物与无机酸或有机酸形成的在药学上可接受的盐。
本发明的另一优选方案是，在上述方案的基础上，所述无机酸为氢氟酸、盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸、碳酸，硼酸、亚硒酸、磷钼酸、亚磷酸或亚硫酸。
本发明的另一优选方案是，在上述方案的基础上，所述有机酸为柠檬酸、马来酸、D-苹果酸、L-苹果酸、DL-苹果酸、L-乳酸、D-乳酸、DL-乳酸、草酸、甲磺酸、戊酸、油酸、月桂酸、对甲基苯磺酸、1-萘磺酸、2-萘磺酸、酞酸、酒石酸、丙二酸、丁二酸、富马酸、乙醇酸、硫醇酸、甘氨酸、肌氨酸、磺酸、烟酸、甲基吡啶酸、异烟酸、二氯乙酸、苯甲酸或取代苯甲酸。
本发明的另一优选方案是，在上述方案的基础上，包括所述小白菊内酯-苯磺酰基呋咱衍生物与R8Z形成的季铵盐，Z为氟、氯、溴、碘、对甲苯磺酸酯基、甲磺酸酯基、苯磺酸酯基或三氟甲基磺酸酯基；R8为烃基、环烷基、羟基取代烷基、烯基、炔基、芳基、杂环基、芳基取代烷基、芳基烯基、芳基炔基、氰基取代甲基、烷氧基取代烷基或芳氧取代烷基。
本发明的另一优选方案是，在上述方案的基础上，还提供如式(Ⅱ)–(Ⅷ)任意一项化学式所示的小白菊内酯-苯磺酰基呋咱衍生物，
(Ⅷ)中R4为-NR6R7；其中R6和R7可以相同或不同，分别为氢、烷基、环烷基、羟基取代烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基、杂环基、三氟甲基、多氟取代烷基、腈基、腈基甲基、酰基、氨基甲酰基、磺酰基、磺酰胺基或芳氧烷基；R6、R7和N原子形成环状结构，环优选为3–9元环，环状结构上可以被一个或多个取代基取代，包括氢、烷基、环烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基或杂环基；
及式(Ⅱ)–(Ⅷ)所示化合物与无机酸或有机酸形成的在药学上可接受的盐，包括与R8Z形成的季铵盐，Z为氟、氯、溴、碘、对甲苯磺酸酯基、甲磺酸酯基、苯磺酸酯基或三氟甲基磺酸酯基；R8为烃基、环烷基、羟基取代烷基、烯基、炔基、芳基、杂环基、芳基取代烷基、芳基烯基、芳基炔基、氰基取代甲基、烷氧基取代烷基或芳氧取代烷基；无机酸或有机酸为氢氟酸、盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸、碳酸，硼酸、亚硒酸、磷钼酸、亚磷酸、亚硫酸、柠檬酸、马来酸、D-苹果酸、L-苹果酸、DL-苹果酸、L-乳酸、D-乳酸、DL-乳酸、草酸、甲磺酸、戊酸、油酸、月桂酸、对甲基苯磺酸、1-萘磺酸、2-萘磺酸、酞酸、酒石酸、丙二酸、丁二酸、富马酸、乙醇酸、硫醇酸、甘氨酸、肌氨酸、磺酸、烟酸、甲基吡啶酸、异烟酸、二氯乙酸、苯甲酸或取代苯甲酸。
本发明还提供所述小白菊内酯-苯磺酰基呋咱衍生物或其盐在制备抗癌药物或制备辅助抗癌药物中的用途，其中癌症为白血病、乳腺癌、前列腺癌、鼻咽癌、大肠癌、肺癌、肝癌、食道癌、胃癌、肠道癌、肾癌、口腔癌、何杰金淋巴癌、胰腺癌、直肠结肠癌、子宫颈癌、非何杰金淋巴癌、神经胶质瘤、黑瘤、膀胱癌、卵巢癌、甲状腺癌或卡波西肉瘤。
本发明还提供所述小白菊内酯-苯磺酰基呋咱衍生物或其盐与药学上可接受的载体或与其他抗癌药物形成的组合物。
具体实施方式
为了理解本发明，下面结合实施例进一步说明本发明，但本发明的保护范围并不仅限于这些实施例。
实施例1：式(Ⅰ)所示的小白菊内酯-苯磺酰基呋咱衍生物及其盐的合成
化合物1为
实施例中各化合物具体合成路线1-8以及化合物的化学式如下：
其中，化合物6-16按路线1合成，化合物20-22和31-38按路线2合成，化合物47-54按路线3合成，化合物57a-57b和60按路线4合成，化合物62a-62e,65a-65b和66按路线5合成，化合物67-71按路线6合成，化合物72a-72i按路线7合成，化合物73-74按路线8合成。
化合物2的合成
将化合物1(6.0g，35.67mmol)溶于冰乙酸(30.0mL)中，加入30％的过氧化氢溶液(H2O2)(12.0mL),反应体系在室温下搅拌3小时,在0℃下，缓慢的将发烟硝酸(16mL)滴加到上述体系中，90℃下搅拌4小时，冷却至室温，加入少量水，0℃下搅拌30min，产生白色固体，过滤干燥得化合物2(白色固体，3600.0mg，产率50.5％)。1H NMR(400MHz,CDCl3)δ8.15(dd,J＝12.8,7.5Hz,2H),7.89–7.73(m,1H),7.65(dt,J＝15.5,7.9Hz,2H)；13C NMR(100MHz,CDCl3)δ155.7,137.1,136.3,136.2,136.0,130.3,130.0,129.7,129.2,115.2；HRMS(ESI)计算值C14H10N2NaO6S2[M+Na]+388.9872,测量值388.9878.
化合物4的合成
依次取化合物3(30g，121mmol)和二氧化硒(7.6g，68mmol)于反应瓶中，加入二氯甲烷(563mL)，室温下开始搅拌，将预先用无水硫酸镁和无水硫酸钠干燥的过氧化氢叔丁醇(27g，304mmol)加入到上述体系中，反应体系在室温下反应4天，通过TLC检测反应完全后，加过量的饱和硫代硫酸钠，搅拌10分钟，分离有机相，用二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至2:1)得到化合物4(白色无定型固体，20g，产率：62.5％)。1H NMR(400MHz,CDCl3)δ6.15(d,J＝3.5Hz,1H),5.60(t,J＝8.2Hz,1H),5.52(d,J＝3.2Hz,1H),4.05(dd,J＝32.1,12.9Hz,2H),3.81(t,J＝9.4Hz,1H),2.86–2.76(m,2H),2.48–2.39(m,1H),2.37–2.31(m,3H),2.29–2.20(m,1H),2.20–2.13(m,1H),2.12–2.05(m,1H),1.65–1.55(m,1H),1.49(s,3H),1.03(t,J＝12.4Hz,1H).13C NMR(100MHz,CDCl3)δ169.9,139.5,138.8,126.8,120.4,81.4,65.4,63.3,60.4,42.7,36.8,25.5,24.0,23.6,18.0.HRMS(ESI)计算值C15H20NaO4[M+Na]+287.1254,测量值287.1258.
化合物5的合成
依次取化合物4(10g，3.78mmol)和丁二酸酐(0.45g，4.54mmol)，4-二甲氨基吡啶(0.46g，3.78mmol)于反应瓶中，加入二氯甲烷(50mL)，室温下搅拌8小时，通过TLC检测反应完全后，加1N的盐酸调pH到3，分离有机相，用二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物5(白色无定型固体，11.2g，产率：78.5％)。1H NMR(400MHz,CDCl3)δ9.40(s,1H),6.12(d,J＝3.4Hz,1H),5.60(t,J＝7.5Hz,1H),5.50(d,J＝2.8Hz,1H),4.60(d,J＝12.5Hz,1H),4.40(d,J＝12.5Hz,1H),3.79(t,J＝9.3Hz,1H),2.81(dd,J＝22.9,9.2Hz,2H),2.67–2.49(m,4H),2.41–2.01(m,6H),1.61(dd,J＝17.7,8.0Hz,1H),1.46(s,3H),1.01(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.0,171.8,169.5,138.5,134.4,130.3,120.2,81.0,80.9,66.9,63.0,60.1,60.0,42.3,36.2,29.3,28.6,28.5,28.2,25.3,24.1,23.5,17.6,16.9.HRMS(ESI)计算值C19H24NaO7[M+Na]+387.1414,测量值387.1418.
化合物6的合成
在0℃下，将乙二醇(67.8mg，1.09mmol)溶于重蒸的THF(3.0mL)中，加入25％NaOH溶液(0.1mL)，搅拌1–2min后，加入苯磺酰基呋咱(2)(100.0mg，0.273mmol)，室温下搅拌8h，用TLC检测反应完全，用饱和氯化铵淬灭反应，乙酸乙酯萃取三次，用无水硫酸镁干燥有机相，过滤，减压浓缩，简单纯化得化合物6a(白色无定型固体，51.0mg，产率65.3％)。
将化合物5(100mg，0.27mmol)溶于二氯甲烷(5.0mL)中，依次加入化合物6a(51.48mg，0.18mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐EDCI(52.3mg，0.27mmol)，4-二甲氨基吡啶DMAP(2.2mg，0.018mmol)，三乙胺(38μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物6(白色无定型固体，95.3mg，产率：83.8％)。1H NMR(400MHz,CDCl3)δ8.06(d,J＝7.7Hz,2H),7.76(t,J＝7.3Hz,1H),7.63(t,J＝7.6Hz,2H),6.23(d,J＝2.9Hz,1H),5.69(t,J＝7.5Hz,1H),5.56(d,J＝2.1Hz,1H),4.68(d,J＝12.5Hz,1H),4.63(d,J＝4.0Hz,2H),4.57–4.42(m,3H),2.91(t,J＝9.3Hz,1H),2.85(d,J＝9.4Hz,1H),2.76–2.58(m,4H),2.50–2.09(m,6H),1.72–1.62(m,1H),1.54(s,3H),1.10(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.0,171.9,169.4,158.6,138.8,137.9,135.7,134.7,130.7,129.7,128.6,120.3,81.0,68.8,67.1,63.2,61.4,59.9,42.6,36.6,29.7,28.8,28.8,25.7,24.5,23.8,18.0.HRMS(ESI)计算值C29H36N3O12S[M+NH4]+650.2014,测量值650.2023.
化合物7的合成
步骤同上，得到化合物7(白色无定型固体，87.6mg，产率：75.2％)。1H NMR(400MHz,CDCl3)δ8.03(d,J＝8.0Hz,2H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.7Hz,2H),6.21(d,J＝3.2Hz,1H),5.67(t,J＝7.9Hz,1H),5.56(d,J＝2.8Hz,1H),4.63(d,J＝12.5Hz,1H),4.49(t,J＝6.0Hz,2H),4.44(d,J＝12.5Hz,1H),4.28(t,J＝6.0Hz,2H),2.95–2.86(m,1H),2.83(d,J＝9.4Hz,1H),2.68–2.54(m,4H),2.49–2.09(m,8H),1.66(dd,J＝17.0,8.1Hz,1H),1.52(s,2H),1.08(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.1,171.9,169.3,158.7,138.7,137.8,135.6,134.6,130.6,129.6,129.3,128.4,120.1,110.4,80.9,67.9,67.0,63.1,60.5,59.9,42.5,36.5,28.8,28.7,27.8,25.6,24.4,23.7,17.9.HRMS(ESI)计算值C30H38N3O12S[M+NH4]+664.2171测量值664.2171.
化合物8的合成
步骤同上，得到化合物8(白色无定型固体，82.3mg，产率：69.2％)。1H NMR(400MHz,CDCl3)δ8.03(d,J＝7.8Hz,2H),7.75(t,J＝7.5Hz,1H),7.69–7.53(m,2H),6.21(d,J＝3.4Hz,1H),5.67(t,J＝8.1Hz,1H),5.56(d,J＝3.0Hz,1H),4.66(d,J＝12.5Hz,1H),4.45(m,3H),4.16(t,J＝6.3Hz,2H),3.84(t,J＝9.3Hz,1H),2.96–2.87(m,1H),2.84(d,J＝9.4Hz,1H),2.66–2.59(m,4H),2.48–2.09(m,6H),1.99–1.90(m,2H),1.81(dt,J＝12.8,6.2Hz,2H),1.66(t,J＝10.6Hz,1H),1.52(s,3H),1.08(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.2,172.0,169.4,158.8,138.7,137.8,135.6,134.6,130.6,129.6,128.4,120.2,110.4,80.9,70.9,67.0,63.9,63.1,59.9,42.5,36.5,28.8,28.8,25.6,25.1,24.8,24.4,23.7,17.9.HRMS(ESI)计算值C31H40N3O12S[M+NH4]+678.2327,测量值678.2328.
化合物9的合成
步骤同上，得到化合物9(白色无定型固体，74.9mg，产率：61.7％)。1H NMR(400MHz,CDCl3)δ8.04(d,J＝7.8Hz,2H),7.76(t,J＝7.3Hz,1H),7.62(t,J＝7.5Hz,2H),6.22(s,1H),5.68(t,J＝7.8Hz,1H),5.56(s,1H),4.66(d,J＝12.5Hz,1H),4.47(d,J＝12.6Hz,1H),4.42(t,J＝6.1Hz,2H),4.12(t,J＝6.2Hz,2H),3.84(t,J＝9.3Hz,1H),2.92(t,J＝9.7Hz,1H),2.84(d,J＝9.4Hz,1H),2.62(s,4H),2.47–2.09(m,6H),1.89(dd,J＝13.7,6.7Hz,2H),1.78–1.62(m,4H),1.53(s,4H),1.09(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ172.4,172.2,169.5,159.1,138.9,138.1,135.8,134.8,130.7,129.8,128.6,120.4,110.6,81.1,71.3,67.2,64.4,63.3,60.0,42.7,36.6,29.0,29.0,28.1,28.1,25.8,24.6,23.9,22.2,18.1.HRMS(ESI)计算值C32H42N3O12S[M+NH4]+692.2484,测量值692.2492.
化合物10的合成
步骤同上，得到化合物10(白色无定型固体，84.5mg，产率：68.1％)。1H NMR(400MHz,CDCl3)δ8.05(d,J＝7.9Hz,2H),7.76(t,J＝7.5Hz,1H),7.62(t,J＝7.8Hz,2H),6.23(d,J＝3.4Hz,1H),5.69(t,J＝8.0Hz,1H),5.57(d,J＝3.0Hz,1H),4.67(d,J＝12.5Hz,1H),4.48(d,J＝12.5Hz,1H),4.42(t,J＝6.4Hz,1H),4.10(t,J＝6.6Hz,2H),3.85(t,J＝9.3Hz,2H),2.93(dd,J＝14.9,5.9Hz,1H),2.85(d,J＝9.4Hz,1H),2.66–2.57(m,4H),2.46–2.13(m,6H),1.92–1.84(m,2H),1.71–1.62(m,3H),1.54(s,3H),1.45(m,4H),1.10(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.3,172.1,169.4,158.9,138.7,137.9,135.6,134.7,130.6,129.6,128.5,120.3,110.4,80.9,71.4,67.0,64.6,63.2,59.9,42.5,36.5,28.9,28.8,28.4,28.2,25.6,25.4,25.2,24.4,23.7,17.9.HRMS(ESI)计算值C31H40N3O12S[M+NH4]+678.2327,测量值678.2328.
化合物11的合成
步骤同上，得到化合物11(白色无定型固体，91.0mg，产率：71.9％)。1H NMR(400MHz,CDCl3)δ8.02(d,J＝7.5Hz,2H),7.75(t,J＝7.5Hz,1H),7.65–7.56(m,2H),6.21(d,J＝3.3Hz,1H),5.67(t,J＝8.0Hz,1H),5.56(d,J＝2.9Hz,1H),4.66(d,J＝12.5Hz,1H),4.46(d,J＝12.5Hz,1H),4.39(t,J＝6.5Hz,2H),4.07(t,J＝6.6Hz,2H),3.83(t,J＝9.3Hz,1H),2.90(t,J＝8.8Hz,1H),2.83(d,J＝9.4Hz,1H),2.61(s,4H),2.48–2.09(m,6H),1.91–1.79(m,2H),1.64(dd,J＝14.6,7.5Hz,3H),1.52(s,3H),1.48–1.25(m,6H),1.08(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.2,172.0,169.3,158.9,138.7,137.9,135.5,134.6,130.5,129.5,128.4,120.1,110.3,80.9,71.4,66.9,64.7,63.1,59.8,42.5,36.5,28.9,28.8,28.6,28.3,28.2,25.6,25.6,25.4,24.4,23.7,17.9.HRMS(ESI)计算值C34H46N3O12S[M+NH4]+720.2797,测量值720.2806.
化合物12的合成
步骤同上，得到化合物12(白色无定型固体，77.1mg，产率：59.7％)。1H NMR(400MHz,CDCl3)δ8.05(d,J＝7.6Hz,2H),7.76(t,J＝7.5Hz,1H),7.62(t,J＝7.8Hz,2H),6.24(d,J＝3.4Hz,1H),5.69(t,J＝8.1Hz,1H),5.57(d,J＝3.0Hz,1H),4.68(d,J＝12.5Hz,1H),4.48(d,J＝12.5Hz,1H),4.41(t,J＝6.5Hz,2H),4.08(t,J＝6.7Hz,2H),3.85(t,J＝9.3Hz,1H),2.97–2.87(m,1H),2.85(d,J＝9.4Hz,1H),2.69–2.57(m,4H),2.47–2.11(m,6H),1.92–1.81(m,2H),1.68–1.59(m,3H),1.54(s,3H),1.44(d,J＝12.1Hz,2H),1.36(s,6H),1.11(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ172.3,172.1,169.4,159.0,138.7,138.1,135.6,134.7,130.6,129.6,128.5,120.2,110.4,81.0,71.5,67.1,64.8,63.2,59.9,42.6,36.5,29.6,29.0,28.9,28.9,28.5,28.3,25.7,25.7,25.5,24.5,23.8,17.9.HRMS(ESI)计算值C35H48N3O12S[M+NH4]+734.2953,测量值734.2958.
化合物13的合成：
步骤同上，得到化合物13(白色无定型固体，171.7mg，产率：87％)。1HNMR(400MHz,CDCl3)δ8.02(d,J＝8.2Hz,2H),7.75(t,J＝7.4Hz,1H),7.60(t,J＝7.7Hz,2H),6.21(d,J＝3.2Hz,1H),5.66(t,J＝8.1Hz,1H),5.56(d,J＝2.7Hz,1H),4.66(d,J＝12.4Hz,1H),4.46(d,J＝12.5Hz,2H),4.38(t,J＝6.5Hz,2H),4.05(t,J＝6.7Hz,1H),3.83(t,J＝9.3Hz,1H),2.89(t,J＝10.1Hz,1H),2.83(d,J＝9.4Hz,1H),2.60(s,4H),2.47–2.09(m,6H),1.89–1.79(m,2H),1.69–1.56(m,3H),1.52(s,3H),1.41(d,J＝7.2Hz,2H),1.31(s,8H),1.08(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ172.4,172.2,169.5,159.1,138.8,138.1,135.7,134.8,130.7,129.7,128.5,120.4,110.5,81.1,71.7,67.2,65.0,63.3,60.0,42.7,36.6,29.4,29.2,29.0,29.0,28.6,28.4,25.9,25.7,25.6,24.5,23.9,18.0.HRMS(ESI)C36H46N2NaO12S[M+Na]+计算值：753.2664，实验值：753.2667。
化合物14的合成：
步骤同上，得到化合物14(白色无定型固体，产率：83％)。1HNMR(400MHz,CDCl3)δ8.05(d,J＝7.9Hz,2H),7.76(t,J＝7.5Hz,1H),7.61(t,J＝7.8Hz,2H),6.24(d,J＝3.4Hz,1H),5.68(t,J＝8.1Hz,1H),5.57(d,J＝3.1Hz,1H),4.68(d,J＝12.4Hz,1H),4.47(d,J＝12.5Hz,1H),4.40(t,J＝6.6Hz,2H),4.07(t,J＝6.8Hz,2H),3.85(t,J＝9.3Hz,1H),2.96–2.87(m,1H),2.85(d,J＝9.4Hz,1H),2.67–2.57(m,4H),2.46–2.11(m,6H),1.90–1.81(m,2H),1.68–1.57(m,3H),1.54(s,3H),1.50–1.40(m,2H),1.31(s,10H),1.10(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ172.5,172.3,169.6,159.2,138.9,138.2,135.7,134.9,130.8,129.8,128.7,120.5,110.6,81.2,71.8,67.2,65.1,63.4,60.1,42.8,36.7,29.5,29.3,29.2,29.1,29.1,28.7,28.5,26.0,25.8,25.7,24.6,23.9,18.1.HRMS(ESI)C37H48N2NaO12S[M+Na]+计算值：767.2820，实验值：767.2825。
化合物15的合成：
化合物15的合成方法同化合物6的合成步骤相同，只是将反应物3a替换为10a，经过简单的后处理和纯化可以得到白色固体化合物15(产率：89％)。1HNMR(400MHz,CDCl3)δ8.04(d,J＝7.7Hz,2H),7.75(t,J＝7.5Hz,1H),7.61(t,J＝7.8Hz,2H),6.22(d,J＝3.4Hz,1H),5.68(t,J＝8.0Hz,1H),5.57(d,J＝3.0Hz,1H),4.67(d,J＝12.4Hz,1H),4.46(d,J＝12.5Hz,1H),4.39(t,J＝6.5Hz,2H),4.06(t,J＝6.7Hz,2H),3.84(t,J＝9.3Hz,1H),2.94–2.86(m,1H),2.84(d,J＝9.5Hz,1H),2.67–2.55(m,4H),2.45–2.11(m,6H),1.90–1.80(m,2H),1.67–1.56(m,3H),1.53(s,3H),1.48–1.38(m,2H),1.28(s,12H),1.09(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.5,172.3,169.5,159.1,138.8,138.1,135.7,134.9,130.8,129.7,128.6,120.5,110.5,81.1,71.7,67.2,65.1,63.3,60.1,42.7,36.7,29.6,29.5,29.3,29.2,29.1,29.0,28.6,28.5,26.0,25.8,25.6,24.5,23.9,18.1.HRMS(ESI)C38H50N2NaO12S[M+Na]+计算值：781.2977，实验值：781.2973。
化合物16的合成：
化合物16的合成方法同化合物6的合成步骤相同，只是将反应物3a替换为11a，经过简单的后处理和纯化可以得到白色固体化合物16(产率：77％)。1HNMR(400MHz,CDCl3)δ8.04(d,J＝8.2Hz,2H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.6Hz,2H),6.23(d,J＝3.2Hz,1H),5.68(t,J＝8.0Hz,1H),5.57(d,J＝2.6Hz,1H),4.68(d,J＝12.4Hz,1H),4.46(d,J＝12.4Hz,1H),4.39(t,J＝6.5Hz,2H),4.05(t,J＝6.7Hz,2H),3.84(t,J＝9.3Hz,1H),2.90(d,J＝9.2Hz,1H),2.84(d,J＝9.5Hz,1H),2.71–2.53(m,4H),2.48–2.10(m,6H),1.92–1.80(m,2H),1.71–1.57(m,3H),1.53(s,3H),1.47–1.38(m,2H),1.27(s,14H),1.09(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ172.5,172.3,169.5,159.1,138.8,138.2,135.7,134.9,130.8,129.7,128.6,120.5,110.5,81.1,71.8,67.2,65.1,63.4,60.1,42.7,36.7,29.6,29.6,29.6,29.3,29.2,29.1,29.0,28.6,28.5,26.0,25.8,25.7,24.5,23.9,18.1.HRMS(ESI)C39H52N2NaO12S[M+Na]+计算值：795.3133，实验值：795.3137。
化合物20的合成
步骤同上，得到化合物20(白色无定型固体，69.1mg，产率：58.3％)1HNMR(400MHz,CDCl3)δ8.04(d,J＝7.7Hz,2H),7.75(t,J＝7.5Hz,1H),7.61(t,J＝7.8Hz,2H),6.21(d,J＝3.4Hz,1H),5.89(q,J＝5.2Hz,2H),5.68(t,J＝8.0Hz,1H),5.55(d,J＝3.1Hz,1H),5.04(d,J＝5.2Hz,2H),4.73(d,J＝5.1Hz,2H),4.67(d,J＝12.5Hz,1H),4.47(d,J＝12.5Hz,1H),3.84(t,J＝9.3Hz,1H),2.97–2.87(m,1H),2.83(d,J＝9.4Hz,1H),2.71–2.56(m,4H),2.48–2.10(m,6H),1.76–1.61(m,1H),1.52(s,3H),1.09(t,J＝12.5Hz,1H)13C NMR(100MHz,CDCl3)δ171.9,171.9,169.3,158.4,138.7,137.8,135.6,134.6,130.7,130.1,129.6,128.5,125.8,120.2,110.5,80.9,67.1,66.5,63.2,60.2,59.9,42.6,36.5,28.8,28.7,25.7,24.5,23.7,17.9.HRMS(ESI)计算值C31H38N3O12S[M+NH4]+676.2171,测量值676.2169.
化合物21的合成
步骤同上，得到化合物21(白色无定型固体，77.2mg，产率：65.4％)1HNMR(400MHz,CDCl3)δ8.07(d,J＝7.8Hz,2H),7.76(d,J＝7.4Hz,1H),7.64(t,J＝7.8Hz,2H),6.25(d,J＝3.4Hz,1H),5.70(t,J＝8.1Hz,1H),5.57(d,J＝3.1Hz,1H),5.10(s,2H),4.76(s,2H),4.69(d,J＝12.5Hz,1H),4.50(d,J＝12.5Hz,1H),3.85(t,J＝9.3Hz,1H),2.98–2.89(m,1H),2.85(d,J＝9.4Hz,1H),2.74–2.60(m,4H),2.51–2.12(m,6H),1.74–1.63(m,1H),1.55(s,3H),1.11(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ171.8,171.4,169.3,157.9,138.8,137.7,135.7,134.6,130.8,129.7,128.6,120.2,83.6,81.0,78.7,67.2,63.2,59.9,58.5,52.2,42.6,36.6,28.8,28.7,25.7,24.5,23.8,17.9.HRMS(ESI)计算值C31H36N3O12S[M+NH4]+674.2014,测量值674.2006.
化合物22的合成
步骤同上，得到化合物22(白色无定型固体，88.1mg，产率：81.9％)1HNMR(400MHz,CDCl3)δ8.01(d,J＝7.7Hz,2H),7.74(t,J＝7.4Hz,1H),7.60(t,J＝7.7Hz,2H),6.20(d,J＝3.3Hz,1H),5.64(t,J＝7.9Hz,1H),5.55(d,J＝2.9Hz,1H),4.56(d,J＝12.5Hz,1H),4.38(d,J＝12.5Hz,1H),4.15(s,2H),4.03(s,2H),3.82(t,J＝9.3Hz,1H),2.92–2.84(m,1H),2.82(d,J＝9.4Hz,1H),2.60(s,4H),2.47–2.08(m,6H),1.65(dd,J＝17.1,8.2Hz,1H),1.51(s,3H),1.14–1.01(m,7H).13C NMR(100MHz,CDCl3)δ171.9,171.8,169.3,158.9,138.6,137.9,135.6,134.5,130.5,129.6,128.3,120.1,110.3,80.9,75.4,68.6,66.9,63.1,59.8,42.5,36.5,35.2,28.8,28.70,25.5,24.3,23.7,21.3,17.8.HRMS(ESI)计算值C32H42N3O12S[M+NH4]+692.2484,测量值692.2484.
化合物23的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入二乙二醇(85.86mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4–二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物23(白色无定型固体，178.4mg，产率：71.8％)
化合物24的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入三乙二醇(121.58mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物24(白色无定型固体，124.9mg，产率：45.8％)
化合物25的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入2-甲基-2-丙基-1,3-丙二醇(107.08mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物25(白色无定型固体，144.8mg，产率：55.1％)
化合物26的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入对苯二甲醇(111.78mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物26(白色无定型固体，141.2mg，产率：53.0％)
化合物27的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入间苯二甲醇(111.78mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物27(白色无定型固体，155.9mg，产率：58.5％)
化合物28的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入间羟基苯甲醇(100.44mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物28(白色无定型固体，132.7mg，产率：51.4％)
化合物29的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入2-(3-羟基苯基)乙醇(111.78mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物29(白色无定型固体，169.2mg，产率：63.6％)
化合物30的合成
将化合物5(200mg，0.54mmol)溶于二氯甲烷(10.0mL)中，依次加入3-氨基-1-丙醇(60.75mg，0.81mmol)，1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(156.9mg，0.81mmol)，4-二甲氨基吡啶(6.6mg，0.054mmol)，三乙胺(114μL)室温下搅拌12小时，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到化合物30(白色无定型固体，122.5mg，产率：53.0％)
化合物31的合成
在0℃下，将化合物23(180.8mg，0.40mmol)溶于重蒸的THF(3.0mL)中，加入25％NaOH溶液(0.1mL)，搅拌1–2min后，加入苯磺酰基呋咱(2)(75.0mg，0.20mmol)，室温下搅拌8h，用TLC检测反应完全，用饱和氯化铵淬灭反应，乙酸乙酯萃取三次，用无水硫酸镁干燥有机相，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得化合物31(白色无定型固体，111.2mg，产率79.3％)。1H NMR(400MHz,CDCl3)δ8.11–7.95(m,2H),7.75(t,J＝7.5Hz,1H),7.61(dd,J＝10.2,5.4Hz,2H),6.21(d,J＝3.4Hz,1H),5.66(t,J＝8.0Hz,1H),5.56(d,J＝3.1Hz,1H),4.65(d,J＝12.5Hz,1H),4.61–4.49(m,2H),4.46(d,J＝12.5Hz,1H),4.26(dd,J＝10.6,5.9Hz,2H),3.89(dd,J＝9.0,4.7Hz,2H),3.83(t,J＝9.3Hz,1H),3.77(dd,J＝10.8,6.2Hz,2H),2.92(d,J＝9.0Hz,1H),2.84(d,J＝9.4Hz,1H),2.70–2.63(m,2H),2.63–2.55(m,2H),2.44–2.10(m,6H),1.65(t,J＝11.6Hz,1H),1.52(s,3H),1.08(t,J＝12.4Hz,1H).13C NMR(100MHz,CDCl3)δ172.4,172.1,169.5,158.9,138.8,138.0,135.7,134.7,130.6,129.7,128.6,120.3,81.1,70.6,69.4,68.4,67.2,63.8,63.3,60.1,42.7,36.6,28.9,28.9,25.7,24.5,23.9,18.1.HRMS(ESI)计算值C31H36N2NaO13S[M+Na]+699.1836,测量值699.1835.
化合物31的合成
步骤同上，得化合物31(白色无定型固体，81.7mg，产率55.4％)。1H NMR(400MHz,CDCl3)δ8.07(d,J＝7.6Hz,2H),7.77(t,J＝7.5Hz,1H),7.63(t,J＝7.8Hz,2H),6.24(d,J＝3.3Hz,1H),5.69(t,J＝7.9Hz,1H),5.58(d,J＝2.9Hz,1H),4.68(d,J＝12.4Hz,1H),4.62–4.53(m,2H),4.48(d,J＝12.5Hz,1H),4.35–4.19(m,2H),4.00–3.90(m,2H),3.85(t,J＝9.3Hz,1H),3.79–3.65(m,6H),2.93(t,J＝8.8Hz,1H),2.86(d,J＝9.4Hz,1H),2.71–2.57(m,4H),2.48–2.11(m,6H),1.75–1.62(m,1H),1.55(s,3H),1.11(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ172.4,172.2,169.6,159.0,138.8,138.1,135.7,134.8,130.7,129.8,128.7,120.5,81.2,71.0,70.8,69.2,68.6,67.2,64.0,63.4,60.1,42.7,36.7,29.8,29.0,28.9,25.8,24.6,23.9,18.1.HRMS(ESI)计算值C33H40N2NaO14S[M+Na]+743.2092,测量值743.2098.
化合物32的合成
步骤同上，得化合物32(白色无定型固体，90.4mg，产率62.8％)。1HNMR(400MHz,CDCl3)δ8.03(d,J＝8.1Hz,2H),7.75(t,J＝7.4Hz,1H),7.62(t,J＝7.7Hz,2H),6.23(d,J＝3.1Hz,1H),5.66(t,J＝7.9Hz,1H),5.57(s,1H),4.56(d,J＝12.5Hz,1H),4.38(d,J＝12.5Hz,1H),4.25–4.15(m,2H),4.11–4.03(m,2H),3.84(t,J＝9.2Hz,1H),2.90-2.83(m,2H),2.61(s,4H),2.49–2.11(m,6H),1.66(t,J＝12.2Hz,1H),1.53(s,3H),1.46–1.29(m,4H),1.11(d,J＝11.9Hz,1H),1.05(s,3H),0.95(t,J＝6.7Hz,3H).13C NMR(100MHz,CDCl3)δ172.0,171.9,169.4,159.1,138.7,138.0,135.6,134.6,130.6,130.5,129.6,128.4,120.3,110.4,80.9,74.2,67.5,66.9,63.2,59.9,42.6,37.9,36.5,28.9,28.8,25.6,24.5,23.7,18.7,17.9,16.3,14.8.HRMS(ESI)计算值C34H42N2NaO12S[M+Na]+725.2351,测量值725.2355.
化合物33的合成
步骤同上，得化合物33(白色无定型固体，102.1mg，产率70.4％)。1H NMR(400MHz,CDCl3)δ8.00(d,J＝7.3Hz,2H),7.73(d,J＝6.9Hz,1H),7.58(d,J＝6.7Hz,2H),7.52–7.41(m,2H),7.41–7.30(m,2H),6.20(s,1H),5.68(s,1H),5.54(s,1H),5.43(s,2H),5.14(s,2H),4.67(d,J＝11.9Hz,1H),4.47(d,J＝12.4Hz,1H),3.84(t,J＝9.2Hz,1H),2.91(s,1H),2.84(d,J＝9.3Hz,1H),2.66(d,J＝20.0Hz,4H),2.49–2.08(m,6H),1.74–1.59(m,1H),1.53(s,3H),1.08(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ172.1,169.5,158.6,138.8,137.9,136.8,135.7,134.7,133.8,130.7,129.7,128.5,128.5,120.3,110.6,81.1,72.2,67.2,66.1,63.2,60.0,42.6,36.6,29.7,29.0,25.7,24.5,23.8,18.0.HRMS(ESI)计算值C35H36N2NaO12S[M+Na]+731.1881,测量值731.1885.
化合物34的合成
步骤同上，得化合物34(白色无定型固体，87.5mg，产率60.3％)。1HNMR(400MHz,CDCl3)δ8.01(d,J＝8.1Hz,2H),7.74(t,J＝7.1Hz,1H),7.58(t,J＝7.5Hz,2H),7.44-7.37(m,4H),6.20(d,J＝2.4Hz,1H),5.67(t,J＝7.7Hz,1H),5.54(d,J＝1.7Hz,1H),5.44(s,2H),5.16(s,2H),4.67(d,J＝12.4Hz,1H),4.46(d,J＝12.5Hz,1H),3.84(t,J＝9.2Hz,1H),2.91(t,J＝9.1Hz,1H),2.84(d,J＝9.4Hz,1H),2.70(d,J＝6.3Hz,2H),2.64(d,J＝5.8Hz,2H),2.48–2.11(m,6H),1.69–1.60(m,1H),1.53(s,3H),1.08(t,J＝12.6Hz,2H).13C NMR(100MHz,CDCl3)δ172.0,171.9,169.4,158.5,138.7,137.8,136.4,135.6,134.6,134.1,130.6,129.6,129.0,128.6,128.4,127.9,127.6,120.2,110.4,80.9,72.2,67.0,66.0,63.1,59.9,42.5,36.4,28.8,25.6,24.4,23.7,17.9.HRMS(ESI)计算值C35H36N2NaO12S[M+Na]+731.1881,测量值731.1885.
化合物35的合成
步骤同上，得化合物35(白色无定型固体，74.6mg，产率52.5％)。1HNMR(400MHz,CDCl3)δ8.09(d,J＝7.5Hz,2H),7.80(t,J＝7.5Hz,1H),7.66(t,J＝7.8Hz,2H),7.44(t,J＝7.9Hz,1H),7.33(s,1H),7.29(d,J＝7.6Hz,2H),6.21(d,J＝3.5Hz,1H),5.69(t,J＝8.0Hz,1H),5.54(d,J＝3.1Hz,1H),5.16(s,2H),4.68(d,J＝12.4Hz,1H),4.46(d,J＝12.5Hz,1H),3.84(t,J＝9.3Hz,1H),2.99–2.82(m,2H),2.71(dd,J＝9.4,4.0Hz,2H),2.64(dt,J＝7.0,3.8Hz,2H),2.47–2.09(m,6H),1.65(dd,J＝14.3,12.2Hz,1H),1.54(s,3H),1.10(t,J＝12.4Hz,1H).13C NMR(100MHz,CDCl3)δ172.1,172.1,169.5,158.5,152.7,138.8,138.6,137.9,136.0,134.8,131.0,130.3,129.9,128.8,126.2,120.4,119.7,119.3,110.9,81.1,67.3,65.5,63.3,60.0,42.7,36.6,29.0,25.8,24.5,23.9,18.1,1.1.HRMS(ESI)计算值C34H34N2NaO12S[M+Na]+717.1725,测量值717.1729.
化合物36的合成
步骤同上，得化合物36(白色无定型固体，84.1mg，产率57.9％)。1HNMR(400MHz,CDCl3)δ7.92(d,J＝7.7Hz,2H),7.72(t,J＝7.4Hz,1H),7.56(t,J＝7.8Hz,2H),7.33(d,J＝8.3Hz,2H),7.06(d,J＝8.3Hz,2H),6.19(d,J＝3.2Hz,1H),5.68(t,J＝7.8Hz,1H),5.52(d,J＝2.8Hz,1H),4.70(d,J＝12.4Hz,1H),4.59(t,J＝6.3Hz,2H),4.50(d,J＝12.5Hz,1H),3.83(t,J＝9.3Hz,1H),3.17(t,J＝6.3Hz,2H),2.96–2.85(m,3H),2.82(d,J＝9.4Hz,1H),2.78–2.66(m,2H),2.42–2.07(m,6H),1.67–1.57(m,1H),1.52(s,3H),1.06(t,J＝12.7Hz,1H).13C NMR(101MHz,CDCl3)δ172.0,171.1,169.5,158.9,149.7,138.8,138.0,135.7,134.7,134.6,130.8,130.3,129.8,128.4,121.7,120.5,110.5,81.1,71.6,67.3,63.3,60.0,42.7,36.6,34.3,29.3,29.1,25.7,24.4,23.8,18.0.HRMS(ESI)计算值C35H36N2NaO12S[M+Na]+731.1881,测量值731.1889.
化合物37的合成
步骤同上，得化合物37(白色无定型固体，107.3mg，产率81.2％)。1H NMR(400MHz,CDCl3)δ8.08(t,J＝8.8Hz,2H),7.78(t,J＝7.5Hz,1H),7.65(t,J＝7.6Hz,2H),6.49(s,1H),6.23(d,J＝3.2Hz,1H),5.73–5.54(m,2H),4.62(d,J＝12.6Hz,1H),4.54(dd,J＝11.3,5.7Hz,2H),4.48(d,J＝12.6Hz,1H),3.84(t,J＝9.3Hz,1H),3.56(dd,J＝11.3,5.7Hz,2H),2.95(t,J＝9.1Hz,1H),2.86(d,J＝9.4Hz,1H),2.71–2.60(m,2H),2.60–2.49(m,2H),2.41(t,J＝9.1Hz,1H),2.35–2.08(m,6H),1.72–1.60(m,1H),1.54(d,J＝6.0Hz,3H),1.10(t,J＝12.8Hz,1H).13C NMR(100MHz,CDCl3)δ172.9,171.8,169.6,138.9,137.6,136.0,134.9,130.4,129.9,128.7,120.5,110.5,81.2,71.4,67.0,63.3,60.1,42.7,37.6,36.7,30.5,29.8,29.4,28.5,25.8,24.6,23.9,18.1.HRMS(ESI)计算值C30H35N3NaO11S[M+Na]+668.1885,测量值668.1886.
化合物47的合成
依次取化合物4(10g，3.78mmol)和戊二酸酐(0.52g，4.54mmol)，4-二甲氨基吡啶(0.46g，3.78mmol)于反应瓶中，加入二氯甲烷(50mL)，室温下搅拌8小时，通过TLC检测反应完全后，加1N的盐酸调pH到2-3，分离有机相，用二氯甲烷萃取水相三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至1:1)得到白色固体化合物39，直接投下一步。在25mL圆底烧瓶中依次加入化合物10a(123.8mg,0.3mmol)，化合物39(170mg,0.45mmol)，EDCI(86.3mg,0.45mmol)和DAMP(0.36mg,0.003mmol)，加入无水二氯甲烷5mL,最后加入三乙胺(62uL,0.45mmol)。反应过夜，点板反应基本法完毕，加饱和碳酸氢钠淬灭反应，二氯甲烷萃取三次，合并有机相干燥旋干过柱(PE:EA＝1：1)，得到白色固体化合物47(192mg,83％)，1H NMR(400MHz,CDCl3)δ8.03(dd,J＝8.4,1.1Hz,2H),7.73(d,J＝7.5Hz,1H),7.60(t,J＝7.9Hz,2H),6.22(d,J＝3.5Hz,1H),5.66(t,J＝8.0Hz,1H),5.53(d,J＝3.2Hz,1H),4.63(d,J＝12.5Hz,1H),4.45(d,J＝12.5Hz,1H),4.39(t,J＝6.6Hz,2H),4.04(t,J＝6.8Hz,2H),3.83(t,J＝9.3Hz,1H),2.93–2.79(m,2H),2.48–2.09(m,10H),1.93(p,J＝7.4Hz,2H),1.88–1.79(m,2H),1.71–1.55(m,3H),1.52(s,3H),1.41(dd,J＝13.9,6.2Hz,2H),1.28(s,12H),1.08(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ173.0,172.7,169.4,159.1,138.9,138.2,135.7,134.9,130.7,129.7,128.6,128.5,120.3,110.5,81.1,71.7,66.7,64.7,63.3,60.0,42.7,36.7,33.3,29.5,29.5,29.3,29.1,28.7,28.5,26.0,25.8,25.6,24.5,23.9,20.2,18.1.
化合物48的合成
步骤同上，得化合物47(白色无定型固体，114mg，产率85％)。1H NMR(400MHz,CDCl3)δ8.08–8.03(m,2H),7.78–7.72(m,1H),7.61(dd,J＝10.8,5.0Hz,2H),6.25(d,J＝3.5Hz,1H),5.68(t,J＝8.0Hz,1H),5.55(d,J＝3.2Hz,1H),4.65(d,J＝12.5Hz,1H),4.46(d,J＝12.5Hz,1H),4.41(t,J＝6.6Hz,2H),4.05(t,J＝6.8Hz,2H),3.84(t,J＝9.3Hz,1H),2.93–2.80(m,2H),2.52–2.11(m,10H),1.92–1.80(m,2H),1.69–1.57(m,7H),1.54(s,3H),1.44(dd,J＝15.0,7.1Hz,2H),1.30(s,12H),1.10(t,J＝12.4Hz,1H).13C NMR(100MHz,CDCl3)δ173.5,173.1,169.4,159.2,138.9,138.3,135.7,135.1,130.8,129.8,128.7,120.4,110.6,81.1,71.8,66.7,64.7,63.4,60.0,42.8,36.8,34.0,29.6,29.6,29.4,29.2,28.8,28.6,26.0,25.9,25.7,24.6,24.5,24.0,18.1.
化合物49的合成
步骤同上，得化合物47(白色无定型固体，75mg，产率63％)。1HNMR(400MHz,CDCl3)δ8.04(dd,J＝8.4,1.1Hz,2H),7.80–7.72(m,1H),7.61(t,J＝7.9Hz,2H),6.23(d,J＝3.5Hz,1H),5.71(t,J＝8.0Hz,1H),5.55(d,J＝3.2Hz,1H),4.75(d,J＝12.3Hz,1H),4.53(d,J＝12.3Hz,1H),4.40(t,J＝6.6Hz,2H),4.24(d,J＝2.5Hz,2H),4.20(d,J＝3.3Hz,2H),4.14(t,J＝6.8Hz,2H),3.84(t,J＝9.3Hz,1H),2.91–2.79(m,2H),2.51–2.11(m,6H),1.90–1.79(m,2H),1.68–1.60(m,3H),1.53(s,3H),1.43(dd,J＝14.9,7.0Hz,2H),1.29(s,12H),1.10(t,J＝12.4Hz,1H).13C NMR(100MHz,CDCl3)δ169.8,169.6,169.4,159.2,138.8,138.3,135.7,134.6,131.7,129.7,128.6,120.4,,110.6,81.1,71.8,68.3,68.2,67.3,65.4,63.4,60.0,42.7,36.7,29.5,29.3,29.2,28.6,28.5,25.9,25.8,25.7,24.5,24.0,18.1.
化合物50的合成
步骤同上，得化合物47(白色无定型固体，133mg，产率90％)。1HNMR(400MHz,CDCl3)δ8.04(d,J＝7.5Hz,2H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.6Hz,2H),6.23(s,1H),5.67(t,J＝7.7Hz,1H),5.54(s,1H),4.63(d,J＝12.5Hz,1H),4.41(dd,J＝15.9,9.5Hz,3H),4.03(t,J＝6.5Hz,2H),3.83(d,J＝9.3Hz,1H),2.85(t,J＝8.7Hz,2H),2.51–2.10(m,10H),1.91–1.79(m,2H),1.71–1.56(m,3H),1.53(s,3H),1.42(d,J＝6.0Hz,2H),1.28(s,12H),1.07(d,J＝17.7Hz,7H).13C NMR(100MHz,CDCl3)δ172.0,171.6,169.5,159.1,138.8,138.2,135.7,135.0,130.6,129.7,128.6,120.4,110.5,81.1,71.7,66.4,64.4,63.4,60.0,45.2,45.0,42.7,36.7,32.7,29.6,29.5,29.3,29.2,28.7,28.5,27.8,27.8,26.0,25.8,25.7,24.5,23.9,18.1.
化合物51的合成
步骤同上，得化合物47(白色无定型固体，107mg，产率86％)。1HNMR(400MHz,CDCl3)δ8.04(d,J＝7.5Hz,2H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.4Hz,2H),6.23(s,1H),5.66(t,J＝7.5Hz,1H),5.55(s,1H),4.63(d,J＝12.4Hz,1H),4.41(dd,J＝13.8,9.3Hz,3H),4.02(t,J＝6.2Hz,2H),3.84(t,J＝9.2Hz,1H),2.87(dd,J＝19.8,9.6Hz,2H),2.61–2.46(m,4H),2.45–2.10(m,6H),1.90–1.80(m,2H),1.63(t,J＝17.2Hz,11H),1.53(s,3H),1.42(d,J＝5.8Hz,2H),1.26(d,J＝19.3Hz,12H),1.08(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ172.4,172.0,169.5,159.2,138.9,138.2,135.7,135.1,130.4,129.7,128.6,120.4,110.6,81.1,71.8,66.4,64.4,63.4,60.1,43.1,42.7,42.2,38.2,38.1,36.7,29.6,29.5,29.3,29.2,28.7,28.5,26.0,25.8,25.7,24.5,24.1,23.9,18.1.
化合物52的合成
步骤同上，得化合物47(白色无定型固体，93mg，产率77％)。1HNMR(400MHz,CDCl3)δ8.03(d,J＝7.7Hz,2H),7.75(t,J＝7.4Hz,1H),7.60(t,J＝7.5Hz,2H),6.21(s,1H),5.66(t,J＝7.6Hz,1H),5.54(s,1H),4.62(d,J＝12.5Hz,1H),4.39(t,J＝10.3Hz,3H),4.01(t,J＝6.2Hz,2H),3.83(t,J＝9.2Hz,1H),2.86(dd,J＝24.1,10.1Hz,2H),2.59–2.45(m,4H),2.26(ddt,J＝28.9,17.2,9.0Hz,6H),1.89–1.78(m,2H),1.70–1.54(m,3H),1.52(s,3H),1.49–1.37(m,12H),1.28(s,12H),1.07(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ172.2,171.8,169.5,159.1,138.9,138.2,135.7,135.1,130.4,129.7,128.6,120.3,110.5,81.1,71.7,66.3,64.3,63.3,60.0,42.7,41.2,36.7,35.9,35.4,29.6,29.5,29.3,29.2,28.7,28.5,26.0,25.8,25.7,25.6,24.5,23.9,21.5,18.1.
化合物53的合成
步骤同上，得化合物47(113mg，产率72％)。1HNMR(400MHz,CDCl3)δ8.05(d,J＝8.1Hz,2H),7.75(t,J＝7.1Hz,2H),7.63(dt,J＝16.2,5.9Hz,3H),7.54(dd,J＝5.1,3.5Hz,2H),6.14(d,J＝3.1Hz,1H),5.78(t,J＝8.0Hz,1H),5.48(d,J＝2.6Hz,1H),4.93(d,J＝12.3Hz,1H),4.67(d,J＝12.3Hz,1H),4.41(t,J＝6.5Hz,2H),4.35–4.19(m,2H),3.84(t,J＝9.3Hz,1H),2.89(t,J＝10.8Hz,2H),2.55–2.10(m,6H),1.91–1.81(m,2H),1.78–1.69(m,2H),1.63(dd,J＝19.7,7.7Hz,1H),1.55(s,3H),1.41(dd,J＝14.3,7.7Hz,4H),1.31(s,10H),1.13(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ169.5,167.8,167.3,159.2,138.7,138.3,135.7,135.0,132.5,131.8,131.4,131.2,129.8,129.2,128.7,120.4,110.6,81.1,71.8,68.4,66.0,63.5,60.0,42.8,36.8,29.8,29.6,29.6,29.4,29.2,28.7,28.5,26.1,25.9,25.7,24.7,24.0,18.1.
化合物54的合成
步骤同上，得化合物47(104mg，产率81％)。1H NMR(400MHz,CDCl3)δ8.28(s,1H),8.17(s,1H),8.05(d,J＝8.1Hz,2H),7.99–7.86(m,2H),7.75(t,J＝7.3Hz,1H),7.68–7.56(m,4H),6.12(d,J＝3.2Hz,1H),5.81(t,J＝8.1Hz,1H),5.50(d,J＝2.7Hz,1H),4.98(d,J＝12.3Hz,1H),4.72(d,J＝12.3Hz,1H),4.40(t,J＝6.5Hz,2H),4.33(dd,J＝14.6,7.2Hz,2H),3.86(t,J＝9.3Hz,1H),2.93(dd,J＝19.0,9.3Hz,2H),2.60–2.11(m,6H),1.92–1.73(m,4H),1.68(dd,J＝20.4,10.4Hz,1H),1.56(s,3H),1.44(s,4H),1.33(s,10H),1.15(t,J＝12.9Hz,1H).13C NMR(101MHz,CDCl3)δ169.5,167.9,167.5,159.2,138.7,138.3,135.7,135.1,133.5,133.4,131.3,130.5,129.9,129.8,128.9,128.9,128.8,128.7,128.7,128.4,120.5,110.6,81.2,71.8,68.4,66.0,63.5,60.0,42.9,36.8,29.6,29.6,29.4,29.2,28.8,28.5,26.1,25.9,25.7,24.7,24.1,18.1.
化合物56a的合成：
将间苯二甲酸55a(1.0g,6.0mmol)溶于10mL无水DMF中，冰水浴下搅拌，分批加入NaH(240mg,6mmol),搅拌五分钟后，加入SEM-Cl(1.17mL,6mmol),继续搅拌4h后，TLC检测反应，基本反应完毕。用1N的盐酸溶液调节pH到2–3，乙酸乙酯萃取三次，饱和食盐水洗三次，无水硫酸钠干燥，过滤，旋干，简单纯化直接投下一步。将MMB(300mg,1.14mmol)和上一步的酸(673mg,2.27mmol)共同溶于10mL无水DCM中，依次加入DMAP(13.9mg,0.11mmol)和DIC(0.35mL,2.27mmol),室温下反应过夜，加饱和碳酸氢钠溶液淬灭反应，DCM萃取三次，无水硫酸钠干燥，过滤，旋干，过硅胶柱纯化[PE/EA＝3:1-2:1],得到白色固体化合物56a(378mg,产率61％)。1H NMR(400MHz,CDCl3)δ8.66(s,1H),8.21(dd,J＝15.1,7.7Hz,2H),7.53(t,J＝7.7Hz,1H),6.17(d,J＝3.0Hz,1H),5.76(t,J＝8.1Hz,1H),5.51(d,J＝6.2Hz,3H),4.91(d,J＝12.5Hz,1H),4.72(d,J＝12.5Hz,1H),3.92–3.68(m,3H),2.91(t,J＝9.2Hz,1H),2.85(d,J＝9.4Hz,1H),2.56–2.09(m,6H),1.69(t,J＝11.9Hz,1H),1.52(s,3H),1.08(q,J＝10.1Hz,1H),1.01–0.92(m,2H),-0.02(s,9H).13C NMR(100MHz,CDCl3)δ169.3,165.4,165.2,138.7,134.7,134.2,134.0,131.0,130.9,130.7,130.4,128.9,120.4,89.9,81.0,68.2,67.4,63.3,60.0,42.7,36.6,25.7,24.4,23.9,18.1,18.0,-1.4.
化合物56b的合成：
化合物56b的合成方法同化合物56a的合成步骤相同，只是将间苯二酸替换为5–甲基间苯二酸，经过简单的后处理和纯化可以得到白色固体化合物56b(产率：54％)。1H NMR(400MHz,CDCl3)δ8.49(s,1H),8.05(d,J＝21.7Hz,2H),6.21(d,J＝3.2Hz,1H),5.79(t,J＝8.3Hz,1H),5.60–5.48(m,3H),4.94(d,J＝12.5Hz,1H),4.71(d,J＝12.5Hz,1H),3.86(t,J＝9.5Hz,1H),3.84–3.77(m,2H),2.99–2.91(m,1H),2.88(d,J＝9.4Hz,1H),2.59–2.13(m,9H),1.75–1.66(m,1H),1.55(s,3H),1.12(t,J＝12.9Hz,1H),1.04–0.96(m,2H),0.02(s,9H).13C NMR(100MHz,CDCl3)δ169.4,165.7,165.5,139.1,138.7,134.9,134.9,134.7,131.2,130.7,130.4,128.3,120.5,90.0,81.1,68.3,67.4,63.4,60.0,42.8,36.7,25.8,24.5,24.0,21.3,18.2,18.1,-1.3.
化合物57a的合成：
将化合物56a(514mg,0.947mmol)溶解于9.4mL无水DCM中，冰水浴中搅拌，加入溴化镁乙醚(733.7mg,2.84mmol)，反应4h后点板，反应基本完毕。使用1N盐酸溶液调节pH到2–3，DCM萃取三次，无水硫酸钠干燥，过滤，旋干，过硅胶柱纯化(DCM/MeOH＝50:1),得无色油状物直接投下一步。取上步纯化的酸(111.4mg，0.27mmol)溶于无水二氯甲烷(5.0mL)中，依次加入化合物，10a(468mg,1.13mmol),EDCI(216.6mg,1.13mmol)和DMAP(11.6mg，0.095mmol)，三乙胺(157μL,1.13mmol)室温下搅拌过夜，通过TLC检测反应完全后，用饱和碳酸氢钠溶液淬灭反应，二氯甲烷萃取三次，合并有机相，并用无水硫酸镁干燥，减压浓缩，残留物通过硅胶柱色谱分离纯化(石油醚/乙酸乙酯＝10:1至5:1至3:1)得到白色固体化合物57a(405mg，产率：53％)。1H NMR(400MHz,CDCl3)δ8.67(s,1H),8.22(dd,J＝15.6,7.8Hz,2H),8.05(d,J＝8.1Hz,2H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.7Hz,2H),7.54(t,J＝7.8Hz,1H),6.22(d,J＝3.3Hz,1H),5.80(s,1H),5.53(d,J＝2.9Hz,1H),4.93(d,J＝12.5Hz,1H),4.76(d,J＝12.5Hz,1H),4.40(t,J＝6.5Hz,2H),4.35(t,J＝6.7Hz,2H),3.87(t,J＝9.3Hz,1H),3.00–2.85(m,2H),2.58–2.12(m,6H),1.91–1.74(m,4H),1.73–1.66(m,1H),1.56(s,3H),1.49–1.40(m,4H),1.40–1.29(m,10H),1.13(t,J＝12.8Hz,1H).13C NMR(100MHz,CDCl3)δ169.4,165.8,165.6,159.2,138.7,138.3,135.7,134.9,134.2,133.8,131.3,131.1,130.9,130.4,129.8,128.9,128.7,120.5,110.6,81.1,71.8,67.4,65.7,63.4,60.1,42.8,36.8,29.8,29.6,29.6,29.4,29.2,28.8,28.5,26.1,25.9,25.7,24.6,24.0,18.1.HRMS(ESI)C42H50N2NaO12S[M+Na]+计算值：829.2977，实验值：829.2981。
化合物57b的合成：
化合物57b的合成方法同化合物57a的合成步骤相同，只是将化合物56a替换为化合物56b，经过简单的后处理和纯化可以得到白色固体化合物57b(产率：34％)。1H NMR(400MHz,CDCl3)δ8.47(s,1H),8.03(t,J＝12.5Hz,4H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.8Hz,2H),6.22(d,J＝3.3Hz,1H),5.79(t,J＝8.3Hz,1H),5.52(d,J＝3.0Hz,1H),4.93(d,J＝12.5Hz,1H),4.73(d,J＝12.5Hz,1H),4.37(dt,J＝28.9,6.6Hz,4H),3.87(t,J＝9.3Hz,1H),2.96(t,J＝9.1Hz,1H),2.89(d,J＝9.4Hz,1H),2.57–2.14(m,9H),1.89-1.11(m,5H),1.56(s,3H),1.49–1.40(m,4H),1.32(s,10H),1.13(t,J＝12.8Hz,1H).13C NMR(100MHz,CDCl3)δ169.4,166.0,165.8,159.2,139.0,138.8,138.3,135.7,134.9,134.8,134.4,131.2,131.1,130.3,129.8,128.7,128.1,120.5,81.1,71.8,67.4,65.7,63.5,60.1,42.9,36.8,29.8,29.6,29.6,29.6,29.4,29.2,28.8,28.6,26.1,25.9,25.7,24.6,24.0,21.3,18.1.HRMS(ESI)C43H52N2NaO12S[M+Na]+计算值：843.3133，实验值：843.3136。
化合物59的合成：
化合物59的合成方法同化合物56a的合成步骤相同，只是将间苯二酸替换为对苯二酸，经过简单的后处理和纯化可以得到白色固体化合物59(产率：36％)。1HNMR(400MHz,CDCl3)δ8.07(q,J＝8.6Hz,4H),6.17(d,J＝3.4Hz,1H),5.76(t,J＝8.3Hz,1H),5.51(s,3H),4.89(d,J＝12.5Hz,1H),4.72(d,J＝12.6Hz,1H),3.84(t,J＝9.3Hz,1H),3.80–3.74(m,2H),2.96–2.87(m,1H),2.85(d,J＝9.4Hz,1H),2.55–2.07(m,6H),1.76–1.63(m,1H),1.52(s,3H),1.12–1.03(m,1H),1.00–0.90(m,2H),-0.02(s,9H).13C NMR(100MHz,CDCl3)δ169.3,165.4,165.2,138.7,134.7,134.1,133.8,130.9,129.8,129.6,120.3,90.0,81.0,68.2,67.4,63.2,60.0,42.7,36.6,25.6,24.4,23.9,18.1,18.0,-1.4.
化合物60的合成：
化合物60的合成方法同化合物57a的合成步骤相同，只是将化合物56a替换为化合物59，经过简单的后处理和纯化可以得到白色固体化合物60(产率：41％)。1HNMR(400MHz,CDCl3)δ8.16–7.99(m,6H),7.75(t,J＝7.4Hz,1H),7.61(t,J＝7.5Hz,2H),6.24(d,J＝2.2Hz,1H),5.79(t,J＝8.2Hz,1H),5.54(s,1H),4.92(d,J＝12.6Hz,1H),4.75(d,J＝12.5Hz,1H),4.41(t,J＝6.5Hz,2H),4.34(t,J＝6.5Hz,2H),3.87(t,J＝9.3Hz,1H),2.95(d,J＝10.4Hz,1H),2.89(d,J＝9.5Hz,1H),2.58–2.14(m,6H),1.91–1.67(m,5H),1.56(s,3H),1.48–1.29(m,14H),1.13(t,J＝13.0Hz,1H).13C NMR(100MHz,CDCl3)δ169.4,165.9,165.6,159.2,138.7,138.3,135.7,134.8,134.8,133.6,131.1,129.8,129.7,128.7,120.6,110.6,81.1,71.8,67.5,65.8,63.4,60.1,42.8,36.8,29.6,29.6,29.4,29.2,28.8,28.6,26.1,25.9,25.7,24.6,24.0,18.1.HRMS(ESI)C42H50N2NaO12S[M+Na]+计算值：829.2977，实验值：829.2973。
化合物61a的合成
将MMB(264mg,1.0mmol),PPh3(393mg,1.5mmol)和香豆酸(210mg,1.5mmol)放于反应瓶中，置换氩气，加入无水THF(10mL)溶解，冰水浴下搅拌加入DIAD(0.3mL,1.5mmol)，缓慢升温到室温，室温下搅拌4h，取样点板，反应基本完毕，加饱和氯化铵溶液淬灭反应，EA萃取三次，合并有机相饱和食盐水洗三次，干燥，过滤，浓缩硅胶柱层析纯化的白色固体化合物61a(285mg,产率69％)。1HNMR(400MHz,CDCl3)δ7.62(d,J＝15.9Hz,1H),7.38(d,J＝8.5Hz,2H),7.13-6.99(m,1H),6.87(d,J＝8.4Hz,2H),6.26(d,J＝8.9Hz,1H),6.23(d,J＝3.6Hz,1H),5.72(t,J＝7.9Hz,1H),5.57(d,J＝3.3Hz,1H),4.76(d,J＝12.5Hz,1H),4.59(d,J＝12.5Hz,1H),3.89(t,J＝9.3Hz,1H),2.98(t,J＝9.1Hz,1H),2.91(d,J＝9.4Hz,1H),2.51–2.11(m,6H),1.73–1.64(m,1H),1.55(s,3H),1.12(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.9,167.3,158.6,145.7,138.5,134.9,130.6,130.1,126.3,120.8,116.0,114.1,81.2,66.8,63.3,60.3,42.6,36.5,25.8,24.5,23.8,17.9.HRMS(ESI)calcdfor C24H30NO6[M+NH4]+428.2068,found428.2067.
化合物61b的合成
合成方法同化合物61a，白色固体(产率:55％).1H NMR(400MHz,CDCl3)δ7.62(d,J＝15.9Hz,1H),7.07(dd,J＝8.2,1.8Hz,1H),7.00(d,J＝1.8Hz,1H),6.92(d,J＝8.2Hz,1H),6.25(dd,J＝9.7,6.2Hz,2H),5.88(s,1H),5.75(t,J＝8.3Hz,1H),5.56(d,J＝3.2Hz,1H),4.78(d,J＝12.4Hz,1H),4.60(d,J＝12.5Hz,1H),3.94(s,3H),3.88(t,J＝9.3Hz,1H),3.09–2.98(m,1H),2.91(d,J＝9.4Hz,1H),2.55–2.14(m,6H),1.70(dd,J＝16.9,9.1Hz,1H),1.56(s,3H),1.14(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.4,166.8,148.2,146.8,145.6,138.8,135.0,130.8,126.6,123.2,120.3,114.7,114.6,109.2,81.0,66.9,63.3,60.0,55.9,42.7,36.6,25.8,24.7,23.8,18.0.HRMS(ESI)calcd for C25H29O7[M+H]+441.1908,found 441.1910.
化合物61c的合成
合成方法同化合物61a，白色固体(产率:63％)1H NMR(400MHz,CDCl3)δ7.89(d,J＝16.1Hz,1H),7.32(d,J＝8.6Hz,1H),6.97(s,1H),6.50–6.41(m,2H),6.37(d,J＝16.1Hz,1H),6.22(d,J＝3.5Hz,1H),5.73(t,J＝8.2Hz,1H),5.55(d,J＝3.1Hz,1H),4.74(d,J＝12.5Hz,1H),4.60(d,J＝12.5Hz,1H),3.88(t,J＝9.3Hz,1H),3.81(s,3H),3.11–2.99(m,1H),2.92(d,J＝9.4Hz,1H),2.50–2.12(m,6H),1.65(dd,J＝22.8,9.8Hz,1H),1.55(s,3H),1.12(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ170.1,168.2,160.5,160.2,141.6,138.7,135.3,131.0,130.8,120.9,115.7,114.5,108.2,99.3,81.4,67.0,63.5,60.4,55.6,42.9,36.7,26.1,25.0,24.0,18.1.HRMS(ESI)calcd forC25H28NaO7[M+Na]+463.1727,found 463.1730.
化合物61d的合成
合成方法同化合物61a，黄色固体(产率:54％).1H NMR(400MHz,CDCl3)δ7.58(d,J＝15.9Hz,1H),6.74(s,2H),6.30–6.21(m,2H),5.80(s,1H),5.75(t,J＝8.2Hz,1H),5.55(d,J＝3.2Hz,1H),4.77(d,J＝12.5Hz,1H),4.60(d,J＝12.5Hz,1H),3.92(s,6H),3.88(t,J＝9.3Hz,1H),3.05(ddd,J＝12.0,9.1,3.1Hz,1H),2.91(d,J＝9.4Hz,1H),2.53–2.13(m,6H),1.73–1.66(m,1H),1.56(s,3H),1.14(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ169.5,166.9,147.4,145.9,139.1,137.6,135.3,131.1,125.7,120.4,115.2,105.3,81.2,67.2,63.5,60.1,56.5,43.0,36.8,26.1,25.0,24.0,18.2.HRMS(ESI)calcd forC26H30NaO8[M+Na]+493.1833,found483.1838.
化合物63a的合成
合成方法同化合物61a，白色固体产率:65％。1H NMR(400MHz,CDCl3)δ7.60(d,J＝16.0Hz,1H),7.21(t,J＝7.7Hz,1H),7.11(s,1H),7.01(d,J＝8.2Hz,2H),6.90(d,J＝8.4Hz,1H),6.35(d,J＝16.0Hz,1H),6.23(d,J＝3.0Hz,1H),5.71(t,J＝8.1Hz,1H),5.56(d,J＝2.6Hz,1H),4.74(d,J＝12.5Hz,1H),4.59(d,J＝12.5Hz,1H),3.89(s,1H),3.00(t,J＝9.4Hz,1H),2.89(d,J＝9.4Hz,1H),2.49–2.09(m,6H),1.67(t,J＝10.8Hz,1H),1.54(s,3H),1.10(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ170.2,167.0,156.7,145.7,138.7,135.5,134.9,131.0,130.2,120.9,120.6,118.1,117.5,114.6,81.5,67.3,63.4,60.4,42.8,36.6,25.9,24.8,23.9,18.0.HRMS(ESI)calcd forC24H26NaO6[M+Na]+433.1622,found433.1625.
化合物64的合成
合成方法同化合物55a，白色固体产率:68％。1H NMR(400MHz,CDCl3)δ7.96(d,J＝16.1Hz,1H),7.42(dd,J＝7.8,1.4Hz,1H),7.25–7.19(m,1H),6.90(t,J＝7.5Hz,2H),6.85(d,J＝8.0Hz,1H),6.59(d,J＝16.1Hz,1H),6.22(d,J＝3.5Hz,1H),5.75(t,J＝8.1Hz,1H),5.55(d,J＝3.2Hz,1H),4.76(d,J＝12.4Hz,1H),4.62(d,J＝12.4Hz,1H),3.89(t,J＝9.3Hz,1H),3.16–3.02(m,1H),2.93(d,J＝9.4Hz,1H),2.53–2.13(m,6H),1.68(t,J＝12.5Hz,1H),1.56(s,3H),1.13(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ170.2,167.8,155.8,141.5,138.8,135.3,131.8,131.3,129.7,121.5,120.8,117.9,116.6,81.4,67.5,63.5,60.3,43.0,36.7,29.8,26.2,25.2,24.0,18.2.HRMS(ESI)calcd forC24H26NaO6[M+Na]+433.1622,found433.1625.
化合物4b-9b的合成
将四溴化碳(265.3mg,0.8mmol)和三苯基膦(209.8mg,0.8mmol)共同放入反应瓶中，置换氩气，加入无水二氯甲烷4mL，冰水浴下将4mL无水二氯甲烷溶解的化合物4a-9a(4mmol)加入到反应瓶中，缓慢升温到室温，反应4小时后加入饱和氯化铵溶液淬灭反应，二氯甲烷萃取三次，干燥，浓缩，过硅胶柱层析纯化直接投下一步。
化合物62a的合成
将化合物61a(123.3mg,0.3mmol)和化合物5b(339.0mg,0.9mmol)共同溶解于15mL无水DMF中，加入无水碳酸钾(165.8mg,1.2mmol)，40度下搅拌4小时，反应基本完成，加饱和食盐水淬灭反应，EA萃取三次，合并有机相，饱和食盐水洗三次，干燥，过滤浓缩硅胶柱层析纯化得到白色固体化合物62a(154mg,产率73％)。1H NMR(400MHz,CDCl3)δ8.03(dd,J＝8.4,1.1Hz,2H),7.74(t,J＝7.5Hz,1H),7.68–7.56(m,3H),7.46(d,J＝8.7Hz,2H),6.91(d,J＝8.8Hz,2H),6.28(d,J＝15.9Hz,1H),6.24(d,J＝3.5Hz,1H),5.73(t,J＝8.2Hz,1H),5.56(d,J＝3.2Hz,1H),4.77(d,J＝12.5Hz,1H),4.59(d,J＝12.6Hz,1H),4.50(t,J＝6.1Hz,2H),4.09(t,J＝5.9Hz,2H),3.86(d,J＝9.3Hz,1H),3.03–2.93(m,1H),2.89(d,J＝9.4Hz,1H),2.49–2.12(m,6H),2.12–1.97(m,4H),1.68(dd,J＝13.3,9.0Hz,1H),1.55(s,3H),1.11(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.5,167.0,160.9,159.0,145.2,138.8,138.0,135.8,135.1,130.6,130.0,129.7,128.5,126.9,120.4,114.9,114.9,110.5,81.1,71.3,67.3,66.8,63.3,60.1,42.7,36.7,25.9,25.6,25.4,24.6,23.9,18.1.
化合物62b的合成
合成方法同化合物62a，白色固体，产率：66％。1H NMR(400MHz,CDCl3)δ8.11–7.98(m,2H),7.89(d,J＝16.1Hz,1H),7.75(t,J＝7.5Hz,1H),7.60(t,J＝7.9Hz,2H),7.40(d,J＝8.6Hz,1H),6.51(dd,J＝8.6,2.2Hz,1H),6.46(d,J＝2.2Hz,1H),6.40(d,J＝16.1Hz,1H),6.22(d,J＝3.5Hz,1H),5.73(t,J＝8.1Hz,1H),5.54(d,J＝3.2Hz,1H),4.75(d,J＝12.4Hz,1H),4.59(d,J＝12.5Hz,1H),4.51(t,J＝6.1Hz,2H),4.11(t,J＝6.0Hz,2H),3.93–3.81(m,4H),3.09–2.99(m,1H),2.97–2.85(m,1H),2.50–2.13(m,6H),2.13–1.95(m,4H),1.70–1.62(m,1H),1.55(s,3H),1.13(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.7,162.3,160.2,159.1,141.2,138.8,138.0,135.8,135.4,130.9,130.9,129.8,128.6,120.5,116.4,115.2,110.6,105.9,98.9,81.2,71.4,67.5,67.0,63.4,60.1,55.6,42.9,36.7,26.1,25.8,25.5,25.0,24.0,18.2.
化合物62c的合成
合成方法同化合物62a，白色固体，产率：77％。1HNMR(400MHz,CDCl3)δ8.04(d,J＝8.0Hz,2H),7.74(t,J＝7.4Hz,1H),7.61(dd,J＝16.7,9.9Hz,3H),7.08(d,J＝8.3Hz,1H),7.02(s,1H),6.90(d,J＝8.3Hz,1H),6.27(d,J＝15.4Hz,2H),5.75(t,J＝8.0Hz,1H),5.56(s,1H),4.78(d,J＝12.5Hz,1H),4.60(d,J＝12.5Hz,1H),4.53(t,J＝5.6Hz,2H),4.16(t,J＝5.5Hz,2H),3.93–3.81(m,4H),3.02(t,J＝9.9Hz,1H),2.91(d,J＝9.4Hz,1H),2.58–2.19(m,6H),2.15–2.02(m,4H),1.71(d,J＝8.2Hz,1H),1.56(s,3H),1.14(t,J＝12.9Hz,1H).13CNMR(100MHz,CDCl3)δ169.5,167.0,159.1,150.8,149.7,145.6,139.0,138.2,135.7,135.2,131.0,129.8,128.7,127.4,122.9,120.5,115.2,112.7,110.1,100.1,81.2,71.4,68.4,67.1,63.5,60.1,56.0,42.9,36.8,26.1,25.6,25.6,24.9,24.0,18.2.
化合物62d的合成
合成方法同化合物62a，白色固体，产率：61％。1HNMR(400MHz,CDCl3)δ8.04(d,J＝8.0Hz,2H),7.74(t,J＝7.5Hz,1H),7.66–7.55(m,3H),6.74(d,J＝14.3Hz,2H),6.31(d,J＝15.9Hz,1H),6.23(d,J＝3.3Hz,1H),5.74(t,J＝8.2Hz,1H),5.55(d,J＝3.0Hz,1H),4.77(d,J＝12.5Hz,1H),4.60(d,J＝12.5Hz,1H),4.53(t,J＝6.4Hz,2H),4.07(t,J＝6.0Hz,2H),3.92–3.81(m,7H),3.03(t,J＝8.9Hz,1H),2.90(d,J＝9.4Hz,1H),2.51–2.27(m,4H),2.27–2.09(m,4H),1.91(dt,J＝12.9,6.3Hz,2H),1.72–1.66(m,1H),1.55(s,3H),1.12(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ169.5,166.6,159.1,153.7,145.6,139.4,139.0,138.2,135.7,135.1,131.1,129.8,128.6,120.3,116.7,110.6,105.3,81.2,72.5,71.5,67.2,63.4,60.1,56.2,42.9,36.7,29.8,26.3,26.0,25.3,24.9,24.0,18.1.
化合物62e的合成
合成方法同化合物62a，白色固体，产率：64％。1H NMR(400MHz,CDCl3)δ8.11(d,J＝16.2Hz,1H),8.06–8.00(m,2H),7.75(t,J＝7.5Hz,1H),7.60(t,J＝7.9Hz,2H),6.69(d,J＝16.2Hz,1H),6.19(d,J＝3.5Hz,1H),6.12(s,2H),5.74(t,J＝8.0Hz,1H),5.53(d,J＝3.2Hz,1H),4.72(d,J＝12.4Hz,1H),4.60(d,J＝12.4Hz,1H),4.53(t,J＝6.0Hz,2H),4.13(t,J＝5.9Hz,2H),3.92–3.80(m,7H),3.19–3.06(m,1H),2.94(d,J＝9.4Hz,1H),2.52–2.14(m,6H),2.14–1.98(m,4H),1.70–1.62(m,1H),1.56(s,3H),1.14(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ169.7,168.8,162.4,161.5,159.1,138.8,138.0,136.6,135.8,135.6,131.0,129.8,128.7,120.6,116.3,110.6,105.7,90.9,81.2,71.4,67.4,67.1,63.5,60.2,55.9,42.9,36.8,26.3,25.9,25.5,25.3,24.0,18.2.
化合物65a的合成
合成方法同化合物56a，白色固体，产率：61％。1H NMR(400MHz,CDCl3)δ8.04(d,J＝7.5Hz,2H),7.74(t,J＝7.5Hz,1H),7.69–7.54(m,3H),7.31(t,J＝7.9Hz,1H),7.10(d,J＝7.6Hz,1H),7.04(s,1H),6.96(dd,J＝8.2,1.9Hz,1H),6.40(d,J＝16.0Hz,1H),6.25(d,J＝3.4Hz,1H),5.74(t,J＝8.1Hz,1H),5.56(d,J＝3.1Hz,1H),4.77(d,J＝12.5Hz,1H),4.61(d,J＝12.5Hz,1H),4.52(t,J＝6.1Hz,2H),4.10(t,J＝6.0Hz,2H),3.87(t,J＝9.3Hz,1H),2.98(d,J＝8.9Hz,1H),2.89(d,J＝9.4Hz,1H),2.53–2.13(m,6H),2.13–1.94(m,4H),1.73–1.66(m,1H),1.56(s,3H),1.17–1.10(m,1H).13C NMR(100MHz,CDCl3)δ169.5,166.6,159.3,159.1,145.5,139.0,138.2,135.8,135.7,135.1,131.0,130.2,129.8,128.6,121.2,120.4,117.9,117.2,113.5,110.6,81.2,71.4,67.4,67.2,63.4,60.1,42.9,36.8,26.0,25.8,25.5,24.8,24.0,18.1.
化合物65b的合成：
化合物65b的制备方式同化合物65a的合成步骤相同，只是将化合物63a替换为化合物63b，经过简单的后处理和纯化可以得到无色油状物化合物65b(产率：44％)。1H NMR(400MHz,CDCl3)δ8.04(d,J＝7.8Hz,2H),7.73(t,J＝7.5Hz,1H),7.60(dd,J＝15.4,7.2Hz,3H),7.16–7.02(m,2H),6.87(d,J＝8.3Hz,1H),6.25(dd,J＝11.6,9.9Hz,2H),5.74(t,J＝8.1Hz,1H),5.54(d,J＝3.0Hz,1H),4.74(d,J＝12.6Hz,1H),4.59(d,J＝12.4Hz,1H),4.54(t,J＝5.9Hz,2H),4.15(t,J＝5.9Hz,2H),3.94–3.80(m,4H),3.04(t,J＝8.8Hz,1H),2.90(d,J＝9.4Hz,1H),2.54–2.17(m,6H),2.10(ddd,J＝19.2,13.5,6.9Hz,4H),1.74–1.63(m,1H),1.56(s,3H),1.13(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.5,166.9,159.1,151.9,148.7,145.5,139.1,138.2,135.7,135.3,131.1,129.8,128.7,127.2,123.3,120.3,115.2,111.5,111.5,81.2,71.5,68.5,67.2,63.5,60.1,56.1,42.9,36.8,29.8,26.1,25.7,25.6,25.0,24.0,18.2.HRMS(ESI)C37H40N2NaO12S[M+Na]+计算值：759.2194，实验值：759.2199。
化合物66的合成
合成方法同化合物62a，白色固体，产率：58％。1H NMR(400MHz,CDCl3)δ8.10–7.98(m,3H),7.73(t,J＝7.5Hz,1H),7.59(t,J＝7.8Hz,2H),7.51(d,J＝7.6Hz,1H),7.36(t,J＝7.7Hz,1H),6.97(dd,J＝12.9,7.9Hz,2H),6.48(d,J＝16.1Hz,1H),6.22(d,J＝3.3Hz,1H),5.73(t,J＝8.0Hz,1H),5.55(d,J＝2.9Hz,1H),4.72(d,J＝12.5Hz,1H),4.61(d,J＝12.6Hz,1H),4.52(t,J＝5.7Hz,2H),4.15(t,J＝5.6Hz,2H),3.86(t,J＝9.3Hz,1H),2.99(t,J＝9.0Hz,1H),2.89(d,J＝9.4Hz,1H),2.54–2.17(m,6H),2.15–2.03(m,4H),1.68(t,J＝12.1Hz,1H),1.55(s,3H),1.12(t,J＝12.7Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.1,159.1,157.6,140.9,138.9,138.1,135.7,135.2,132.0,130.7,129.8,128.8,128.7,123.2,121.1,120.5,117.7,112.3,110.6,81.2,71.3,67.8,66.9,63.4,60.1,42.9,36.8,26.0,25.7,25.6,24.9,24.0,18.1.
化合物67的合成
将化合物61c(220mg,0.5mmol)和化合物4b(363.2mg,1mmol)共同溶解于5mL无水DMF中，加入无水碳酸钾(276mg,2mmol)，40度下搅拌4小时，反应基本完成，加饱和食盐水淬灭反应，EA萃取三次，合并有机相，饱和食盐水洗三次，干燥，过滤浓缩硅胶柱层析纯化得到白色固体化合物67(249mg,产率69％)。1H NMR(400MHz,CDCl3)δ8.01–7.95(m,2H),7.90(d,J＝16.1Hz,1H),7.71(t,J＝7.5Hz,1H),7.52(t,J＝7.9Hz,2H),7.42(d,J＝8.6Hz,1H),6.52(d,J＝8.6Hz,1H),6.48(d,J＝2.2Hz,1H),6.42(d,J＝16.1Hz,1H),6.21(d,J＝3.5Hz,1H),5.73(t,J＝8.2Hz,1H),5.54(d,J＝3.1Hz,1H),4.75(d,J＝12.5Hz,1H),4.67–4.55(m,3H),4.21(t,J＝5.8Hz,2H),3.91–3.83(m,4H),3.09–2.98(m,1H),2.90(d,J＝9.4Hz,1H),2.52–2.10(m,8H),1.71–1.62(m,1H),1.55(s,3H),1.12(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.7,162.0,160.2,159.0,141.0,138.9,138.0,135.8,135.4,130.9,130.8,129.8,128.5,120.4,116.7,115.4,110.6,105.9,99.1,81.2,68.1,66.9,63.8,63.4,60.1,55.7,42.8,36.7,28.5,26.1,25.0,24.0,18.1.
化合物68的合成
合成方法同化合物67，白色固体，产率：77％。1H NMR(400MHz,CDCl3)δ8.09–8.01(m,2H),7.90(d,J＝16.1Hz,1H),7.74(t,J＝7.5Hz,1H),7.60(t,J＝7.9Hz,2H),7.40(d,J＝8.6Hz,1H),6.54–6.44(m,2H),6.40(d,J＝16.1Hz,1H),6.23(d,J＝3.5Hz,1H),5.74(t,J＝8.2Hz,1H),5.55(d,J＝3.2Hz,1H),4.76(d,J＝12.4Hz,1H),4.60(d,J＝12.5Hz,1H),4.47(t,J＝6.4Hz,2H),4.05(t,J＝6.2Hz,2H),3.92–3.81(m,4H),3.10–2.99(m,1H),2.92(d,J＝9.4Hz,1H),2.51–2.14(m,6H),2.02–1.85(m,4H),1.74–1.66(m,3H),1.56(s,3H),1.14(t,J＝12.8Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.7,162.5,160.2,159.1,141.2,138.9,138.2,135.8,135.5,130.9,130.9,129.8,128.7,120.5,116.4,115.2,110.6,105.9,99.0,81.2,71.5,67.9,67.0,63.5,60.1,55.7,42.9,36.8,28.8,28.3,26.2,25.0,24.0,22.5,18.2.
化合物69的合成
合成方法同化合物67，白色固体，产率：71％。1H NMR(400MHz,CDCl3)δ8.04(dd,J＝8.4,1.1Hz,2H),7.89(d,J＝16.1Hz,1H),7.78–7.71(m,1H),7.60(t,J＝7.9Hz,2H),7.39(d,J＝8.6Hz,1H),6.49(dd,J＝8.6,2.2Hz,1H),6.45(d,J＝2.2Hz,1H),6.40(d,J＝16.1Hz,1H),6.22(d,J＝3.5Hz,1H),5.73(t,J＝8.2Hz,1H),5.54(d,J＝3.2Hz,1H),4.75(d,J＝12.5Hz,1H),4.59(d,J＝12.5Hz,1H),4.44(t,J＝6.5Hz,2H),4.02(t,J＝6.3Hz,2H),3.91–3.82(m,4H),3.10–2.99(m,1H),2.91(d,J＝9.4Hz,1H),2.53–2.13(m,6H),1.97–1.78(m,4H),1.70–1.62(m,3H),1.55(s,5H),1.13(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.8,162.6,160.2,159.2,141.2,138.9,138.2,135.7,135.4,130.9,130.9,129.8,128.7,120.5,116.3,115.1,110.6,105.9,99.0,81.2,71.6,68.0,67.0,63.5,60.1,55.6,42.9,36.8,29.1,28.5,26.2,25.7,25.5,25.0,24.0,18.2.
化合物70的合成
合成方法同化合物67，白色固体，产率：76％。1H NMR(400MHz,CDCl3)δ8.05(dd,J＝8.4,1.1Hz,2H),7.89(d,J＝16.1Hz,1H),7.74(dd,J＝10.7,4.3Hz,1H),7.61(t,J＝7.9Hz,2H),7.39(d,J＝8.6Hz,1H),6.49(dd,J＝8.6,2.2Hz,1H),6.45(d,J＝2.2Hz,1H),6.40(d,J＝16.1Hz,1H),6.22(d,J＝3.5Hz,1H),5.73(t,J＝8.2Hz,1H),5.54(d,J＝3.2Hz,1H),4.75(d,J＝12.5Hz,1H),4.59(d,J＝12.5Hz,1H),4.42(t,J＝6.5Hz,2H),4.00(t,J＝6.4Hz,2H),3.91–3.81(m,4H),3.09–2.99(m,1H),2.91(d,J＝9.4Hz,1H),2.52–2.11(m,6H),1.85(ddd,J＝29.0,14.0,6.7Hz,4H),1.72–1.61(m,3H),1.55(s,3H),1.53–1.47(m,4H),1.13(t,J＝12.6Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.8,162.6,160.2,159.2,141.3,138.9,138.2,135.7,135.4,130.9,130.9,129.8,128.6,126.0,120.5,116.2,115.0,106.0,99.0,81.2,71.7,68.2,67.0,63.5,60.1,55.6,42.9,36.8,29.2,29.0,28.5,26.2,26.0,25.7,25.0,24.0,18.2.
化合物71的合成
合成方法同化合物67，白色固体，产率：66％。1H NMR(400MHz,CDCl3)δ8.09–8.02(m,2H),7.90(d,J＝16.1Hz,1H),7.75(t,J＝7.5Hz,1H),7.61(t,J＝7.9Hz,2H),7.40(d,J＝8.6Hz,1H),6.49(dd,J＝8.6,2.2Hz,1H),6.45(d,J＝2.1Hz,1H),6.40(d,J＝16.1Hz,1H),6.23(d,J＝3.5Hz,1H),5.74(t,J＝8.1Hz,1H),5.55(d,J＝3.2Hz,1H),4.76(d,J＝12.5Hz,1H),4.60(d,J＝12.5Hz,1H),4.42(t,J＝6.5Hz,2H),4.00(t,J＝6.4Hz,2H),3.91–3.83(m,4H),3.12–3.00(m,1H),2.92(d,J＝9.4Hz,1H),2.51–2.12(m,6H),1.93–1.77(m,4H),1.72–1.63(m,3H),1.56(s,3H),1.49(d,J＝6.2Hz,3H),1.44–1.39(m,3H),1.14(t,J＝12.5Hz,1H).13C NMR(100MHz,CDCl3)δ169.6,167.8,162.7,160.2,159.2,141.3,138.9,138.2,135.7,135.5,130.9,130.9,129.8,128.7,120.5,116.2,115.0,106.0,100.1,99.0,81.2,71.7,68.3,67.0,63.5,60.1,55.6,42.9,36.8,29.3,29.3,29.1,28.5,26.2,26.0,25.6,25.0,24.0,18.2.
化合物72a的合成：
在反应瓶中加入化合物68(105mg,0.14mmol)在冰水浴下加入2N甲胺的四氢呋喃溶液(10mL)。反应液在冰水浴下搅拌1h，TLC检测原料消失后，旋干溶剂，直接过硅胶柱层析(DCM:MeOH＝50:1)纯化得到无色油状物72a(101mg,92％)。1H NMR(400MHz,CDCl3)δ8.05(d,J＝7.5Hz,2H),7.92(d,J＝16.0Hz,1H),7.74(t,J＝7.1Hz,1H),7.60(t,J＝7.4Hz,2H),7.43(d,J＝8.4Hz,1H),6.48(dd,J＝21.3,12.4Hz,3H),5.70(t,J＝8.0Hz,1H),4.87(d,J＝12.8Hz,1H),4.48(dd,J＝17.6,11.4Hz,3H),4.05(s,2H),3.94–3.78(m,4H),2.99(d,J＝12.6Hz,1H),2.82(t,J＝11.4Hz,2H),2.46(s,6H),2.23(d,J＝17.2Hz,5H),2.02–1.84(m,6H),1.70(d,J＝6.7Hz,2H),1.55(s,3H),1.10(t,J＝13.0Hz,1H).13C NMR(100MHz,CDCl3)δ177.4,167.7,162.5,160.2,159.2,141.0,138.2,135.9,135.7,130.8,129.8,129.7,128.7,116.5,115.4,111.8,105.9,99.1,81.6,71.5,67.9,66.2,63.7,60.0,55.7,49.4,46.9,41.5,37.0,36.9,28.8,28.3,26.9,24.6,23.9,22.5,18.1.
化合物72b的合成：
化合物72b的制备方法与化合物72a的合成方法相同，只是将甲胺替换为二甲胺，其他合成及后处理方法相同，得到无色油状物72b，产率87％。1H NMR(400MHz,CDCl3)δ8.03(d,J＝7.7Hz,2H),7.90(d,J＝16.1Hz,1H),7.72(t,J＝7.3Hz,1H),7.58(t,J＝7.6Hz,2H),7.42(d,J＝8.5Hz,1H),6.47(dd,J＝20.0,12.2Hz,3H),5.64(t,J＝7.9Hz,1H),4.83(d,J＝12.8Hz,1H),4.64(d,J＝12.9Hz,1H),4.45(t,J＝6.1Hz,2H),4.03(t,J＝5.8Hz,2H),3.85(s,4H),2.80(d,J＝9.3Hz,1H),2.73(d,J＝12.0Hz,1H),2.61(d,J＝12.4Hz,1H),2.50–2.36(m,4H),2.34–2.08(m,11H),2.00–1.84(m,4H),1.72–1.62(m,2H),1.54(s,3H),1.07(s,1H).13C NMR(100MHz,CDCl3)δ177.1,167.5,162.3,160.0,159.1,140.6,138.1,136.2,135.7,130.6,129.7,128.6,128.4,116.4,115.5,110.5,105.8,98.9,81.2,71.4,67.8,66.1,63.9,60.0,58.4,55.6,45.8,44.6,43.1,37.0,28.7,28.2,27.0,24.8,23.8,22.4,18.0.
化合物72c的合成：
化合物72c的制备方法与化合物72a的合成方法相同，只是将甲胺替换为吡咯烷，其他合成及后处理方法相同，得到无色油状物72c，产率81％。1H NMR(400MHz,CDCl3)δ8.05(d,J＝7.6Hz,2H),7.91(d,J＝15.8Hz,1H),7.74(t,J＝7.1Hz,1H),7.59(t,J＝7.5Hz,2H),7.43(d,J＝8.6Hz,1H),6.47(dd,J＝22.0,12.9Hz,3H),5.65(t,J＝7.9Hz,1H),4.85(d,J＝12.6Hz,1H),4.61(d,J＝12.8Hz,1H),4.47(t,J＝5.9Hz,2H),4.04(t,J＝5.4Hz,2H),3.92–3.78(m,4H),3.01–2.87(m,2H),2.81(d,J＝9.3Hz,1H),2.58(s,4H),2.44(d,J＝9.4Hz,3H),2.30(dd,J＝21.4,9.9Hz,3H),2.17(dd,J＝23.2,9.9Hz,3H),2.01–1.86(m,4H),1.76(s,4H),1.70(d,J＝7.3Hz,2H),1.25(s,3H),1.10(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.1,167.6,162.4,160.1,159.2,140.6,138.2,136.3,135.8,130.7,129.8,128.7,128.6,116.6,115.6,105.9,99.0,81.4,71.5,67.9,66.2,64.1,60.0,55.7,54.4,53.7,45.4,42.4,37.1,29.8,28.8,28.3,26.9,24.7,23.9,23.8,22.5,18.1.
化合物72d的合成：
化合物72d的制备方法与化合物72a的合成方法相同，只是将甲胺替换为哌啶，其他合成及后处理方法相同，得到无色油状物72d，产率85％。1H NMR(400MHz,CDCl3)δ8.03(d,J＝5.5Hz,2H),7.90(d,J＝16.0Hz,1H),7.72(s,1H),7.58(s,2H),7.42(d,J＝7.8Hz,1H),6.46(t,J＝16.5Hz,3H),5.64(s,1H),4.80(dd,J＝30.4,12.7Hz,2H),4.45(s,2H),4.03(s,2H),3.84(s,4H),2.78(t,J＝10.1Hz,2H),2.63(s,2H),2.47–2.22(m,9H),2.21–2.07(m,2H),1.92(d,J＝27.4Hz,4H),1.67(s,2H),1.54(s,8H),1.38(s,2H),1.08(s,1H).13C NMR(100MHz,CDCl3)δ177.5,167.4,162.3,160.0,159.1,140.5,138.1,136.3,135.7,130.6,129.7,128.6,128.0,116.5,115.6,110.5,105.9,98.9,81.3,71.4,67.8,66.2,64.0,60.0,58.1,55.6,54.8,43.9,43.1,37.0,28.7,28.2,27.2,25.9,24.8,24.3,23.8,22.4,18.0.
化合物72e的合成：
化合物72e的制备方法与化合物72a的合成方法相同，只是将甲胺替换为吗啉，其他合成及后处理方法相同，得到无色油状物72e，产率77％。1H NMR(400MHz,CDCl3)δ8.05(d,J＝7.5Hz,2H),7.91(d,J＝16.1Hz,1H),7.74(t,J＝7.5Hz,1H),7.60(t,J＝7.8Hz,2H),7.43(d,J＝8.5Hz,1H),6.55–6.39(m,3H),5.68(t,J＝8.1Hz,1H),4.90(d,J＝12.6Hz,1H),4.66(d,J＝12.6Hz,1H),4.47(t,J＝6.4Hz,2H),4.05(t,J＝6.1Hz,2H),3.86(s,4H),3.68(t,J＝4.4Hz,4H),2.83(dd,J＝17.2,6.5Hz,2H),2.72(dd,J＝13.2,5.4Hz,1H),2.58–2.39(m,7H),2.36–2.12(m,4H),2.04–1.82(m,4H),1.69(dt,J＝15.3,7.6Hz,2H),1.60(s,2H),1.56(s,3H),1.10(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.0,167.6,162.4,160.1,140.9,138.2,136.1,135.8,130.8,129.8,128.9,128.7,116.5,115.4,110.6,105.9,100.1,99.0,81.3,71.5,67.9,67.0,66.2,63.9,60.1,57.5,55.7,54.0,44.0,43.0,37.0,28.8,28.3,27.2,24.7,23.9,22.5,18.1.
化合物72f的合成：
化合物72f的制备方法与化合物72a的合成方法相同，只是将甲胺替换为哌嗪，其他合成及后处理方法相同，得到无色油状物72f，产率71％。1H NMR(400MHz,CDCl3)δ8.04(d,J＝7.9Hz,2H),7.90(d,J＝16.1Hz,1H),7.73(t,J＝7.4Hz,1H),7.59(t,J＝7.7Hz,2H),7.43(d,J＝8.5Hz,1H),6.46(dd,J＝21.1,12.4Hz,3H),5.66(t,J＝8.1Hz,1H),4.86(d,J＝12.7Hz,1H),4.68(d,J＝12.7Hz,1H),4.45(t,J＝6.3Hz,2H),4.03(t,J＝6.1Hz,2H),3.91–3.77(m,4H),2.88(s,4H),2.81(dd,J＝12.6,6.3Hz,2H),2.69(dd,J＝13.0,5.8Hz,1H),2.61–2.35(m,9H),2.34–2.10(m,4H),2.00–1.84(m,4H),1.69(dd,J＝15.1,8.0Hz,2H),1.61–1.50(m,4H),1.09(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.2,167.5,162.4,160.0,159.1,140.7,138.1,136.0,135.7,130.7,129.8,128.6,116.4,115.4,110.6,105.8,98.9,81.3,71.4,67.8,66.2,63.9,60.1,57.6,55.6,54.4,45.8,43.9,42.9,37.0,30.1,29.8,28.7,28.2,27.2,24.7,23.8,22.4,18.1.
化合物72g的合成：
化合物72g的制备方法与化合物72a的合成方法相同，只是将甲胺替换为N-甲基哌嗪，其他合成及后处理方法相同，得到无色油状物72g，产率68％。1HNMR(400MHz,CDCl3)δ8.03(d,J＝7.9Hz,2H),7.90(d,J＝16.1Hz,1H),7.73(t,J＝7.4Hz,1H),7.58(t,J＝7.7Hz,2H),7.42(d,J＝8.5Hz,1H),6.55–6.36(m,3H),5.66(t,J＝8.1Hz,1H),4.82(s,1H),4.71(s,1H),4.45(t,J＝6.3Hz,2H),4.03(t,J＝6.0Hz,2H),3.93–3.76(m,4H),2.87–2.77(m,2H),2.70(dd,J＝13.0,6.8Hz,1H),2.62–2.24(m,14H),2.23(s,3H),2.19–2.07(m,2H),2.00–1.83(m,4H),1.68(dd,J＝15.1,8.0Hz,2H),1.54(s,4H),1.08(t,J＝12.9Hz,1H).13CNMR(100MHz,CDCl3)δ177.1,167.5,162.4,160.0,159.1,140.8,138.1,136.1,135.7,130.7,129.8,128.6,128.5,116.4,115.5,110.6,105.8,98.9,81.2,71.4,67.8,66.3,63.9,60.1,57.,55.6,55.0,53.4,46.0,43.9,43.1,37.0,28.7,28.2,27.2,24.7,23.8,22.4,18.1.
化合物72h的合成：
化合物72h的制备方法与化合物72a的合成方法相同，只是将甲胺替换为N-Boc哌嗪，其他合成及后处理方法相同，得到无色油状物72h，产率77％。1H NMR(400MHz,CDCl3)δ8.03(d,J＝7.8Hz,2H),7.89(d,J＝16.1Hz,1H),7.72(t,J＝7.4Hz,1H),7.58(t,J＝7.8Hz,2H),7.41(d,J＝8.5Hz,1H),6.53–6.37(m,3H),5.65(t,J＝8.0Hz,1H),4.85(d,J＝12.7Hz,1H),4.66(d,J＝12.7Hz,1H),4.45(t,J＝6.3Hz,2H),4.03(t,J＝6.1Hz,2H),3.91–3.78(m,4H),3.40(s,4H),2.86–2.67(m,3H),2.54–2.09(m,13H),2.01–1.83(m,4H),1.67(dt,J＝15.0,7.6Hz,2H),1.54(s,3H),1.41(s,9H),1.08(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.0,167.5,162.4,160.1,159.1,154.8,140.8,138.2,136.0,135.7,130.7,129.7,128.6,128.6,116.4,115.4,110.6,105.9,99.0,81.3,79.6,71.4,67.8,66.1,63.9,60.0,57.2,55.6,53.3,44.1,43.0,37.0,29.8,28.7,28.5,28.2,27.2,24.7,23.8,22.4,18.0.
化合物72i的合成：
化合物72i的制备方法与化合物72a的合成方法相同，只是将甲胺替换为N-Boc哌嗪，其他合成及后处理方法相同，得到无色油状物72i，产率81％。1H NMR(400MHz,CDCl3)δ8.04(d,J＝7.7Hz,2H),7.90(d,J＝16.1Hz,1H),7.73(t,J＝7.4Hz,1H),7.59(t,J＝7.8Hz,2H),7.42(d,J＝8.5Hz,1H),6.46(td,J＝16.2,7.6Hz,3H),5.67(t,J＝8.0Hz,1H),4.85(d,J＝12.6Hz,1H),4.68(d,J＝12.7Hz,1H),4.45(t,J＝6.3Hz,2H),4.04(t,J＝6.1Hz,2H),3.91–3.75(m,4H),3.54(t,J＝5.1Hz,2H),2.87–2.76(m,2H),2.70(dd,J＝12.9,6.9Hz,2H),2.60–2.35(m,13H),2.35–2.07(m,6H),1.99–1.85(m,4H),1.68(dt,J＝9.6,7.5Hz,2H),1.55(s,3H),1.09(t,J＝12.9Hz,1H).13C NMR(100MHz,CDCl3)δ177.1,167.5,162.4,160.0,159.1,140.8,138.1,136.0,135.7,130.6,129.8,128.7,128.6,116.3,115.4,110.6,105.9,98.9,81.2,71.4,67.8,66.4,63.9,60.1,59.2,57.7,57.2,55.6,53.4,52.8,43.9,43.1,37.0,28.7,28.2,27.2,24.7,23.8,22.4,18.1.
化合物73的合成
5mL圆底烧瓶中，加入化合物68(105mg,0.14mmol)，然后加入2.0M二甲氨基的四氢呋喃置于室温下搅拌2h。使用旋转蒸发仪将溶液浓缩，将浓缩液用硅胶柱纯化得到白色固体103mg，将所得固体溶解于乙酸乙酯中，加入15mg富马酸，搅拌过夜，旋干得到白色固体化合物73(108mg,两步产率95％)。1H NMR(400MHz,MeOD-d4)δ8.04(dd,J＝8.5,1.2Hz,2H),7.94(d,J＝16.1Hz,1H),7.80(t,J＝7.5Hz,1H),7.66(t,J＝7.9Hz,2H),7.52(d,J＝8.3Hz,1H),6.71(s,2H),6.62–6.54(m,2H),6.46(d,J＝16.1Hz,1H),5.71(t,J＝8.2Hz,1H),4.87(d,J＝12.8Hz,2H),4.55(d,J＝12.7Hz,1H),4.48(t,J＝6.1Hz,2H),4.13(dt,J＝12.3,7.8Hz,2H),3.88(s,2H),3.39(dd,J＝13.2,9.6Hz,1H),3.24(dd,J＝13.3,4.1Hz,1H),3.06–2.75(m,7H),2.33–2.10(m,4H),1.99–1.86(m,3H),1.69(dt,J＝14.8,7.3Hz,2H),1.58(s,2H),1.07(t,J＝13.0Hz,1H).13C NMR(100MHz,MeOD-d4)δ178.2,169.5,164.3,161.5,160.6,158.7,158.5,142.2,139.6,137.0,136.8,136.0,131.4,130.9,130.6,129.6,115.5,107.6,99.7,83.5,75.3,72.6,69.0,67.4,64.6,61.6,56.2,44.6,43.9,43.1,37.9,36.0,33.7,29.7,29.2,27.8,26.9,25.2,24.6,23.5,21.4,17.9.
化合物74的合成
合成方法同化合物73的制备，两步产率86％。1H NMR(400MHz,DMSO-d6)δ8.01(d,J＝8.1Hz,2H),7.87(t,J＝7.4Hz,1H),7.80(d,J＝16.1Hz,1H),7.72(t,J＝7.6Hz,2H),7.65(d,J＝8.5Hz,1H),6.66–6.55(m,4H),6.50(d,J＝16.1Hz,1H),5.60(t,J＝7.5Hz,1H),4.84(d,J＝12.6Hz,1H),4.61(d,J＝12.6Hz,1H),4.42(t,J＝6.1Hz,2H),4.10–3.98(m,3H),3.85(s,3H),3.63–3.57(m,1H),2.78–2.54(m,4H),2.33(dd,J＝24.0,15.1Hz,8H),2.18–2.01(m,3H),1.80(td,J＝14.6,7.1Hz,5H),1.63(t,J＝10.8Hz,1H),1.54(dd,J＝14.9,7.8Hz,2H),1.48(s,3H),0.93(t,J＝12.7Hz,1H).13C NMR(100MHz,DMSO-d6)δ177.3,166.7,166.0,162.2,159.5,158.9,139.5,137.2,136.1,135.9,134.0,130.4,130.0,128.3,128.3,115.1,114.9,110.5,106.6,98.8,80.5,71.4,67.6,66.3,66.0,63.2,59.9,57.3,56.0,55.7,53.5,42.5,36.6,28.1,27.6,25.8,24.2,23.2,21.8,18.6,17.5.
实施例2：小白菊内酯-苯磺酰呋咱衍生物及其盐对人胰腺癌细胞系Panc-1的抑制作用
将待测试细胞配成2×105/mL细胞悬液，加入96孔板圆底细胞培养板内，分别加入待测化合物，每一测试浓度3孔，置37℃、5％CO2饱和湿度条件下培养72小时，用MTT法在酶联检测仪570nm波长测得吸光度(A)值，计算出本发明化合物对测试癌细胞的抑制作用。
如表1-表4所示，所测试化合物对测试的癌细胞系显示出较强的抗癌活性。
表1小白菊内酯–NO供体杂合物6-16对胰腺癌细胞系Panc-1细胞的抑制作用
| 化合物 | n | IC<sub>50</sub>(μM)<sup>ab</sup> |
| 6 | 1 | 1.484±0.182 |
| 7 | 2 | 2.247±0.837 |
| 8 | 3 | 0.611±0.206 |
| 9 | 4 | 0.787±0.378 |
| 10 | 5 | 0.535±0.120 |
| 11 | 6 | 0.271±0.144 |
| 12 | 7 | 0.201±0.106 |
| 13 | 8 | 0.125±0.035 |
| 14 | 9 | 0.130±0.071 |
| 15 | 10 | 0.067±0.024 |
| 16 | 11 | 0.104±0.024 |
| PTL | - | 4.020±0.113 |
| ADR | - | 0.780±0.435 |
由上表可见，小白菊内酯–NO供体杂合物6-16对胰腺癌细胞系Panc-1细胞的抑制作用十分明显。
表2.小白菊内酯-苯磺酰基呋咱衍生物对胰腺癌细胞系Panc-1的抑制活性(IC50，μM)
由上表可以看出，小白菊内酯-苯磺酰基呋咱衍生物能有效地抑制胰腺癌细胞系Panc-1的活性
表3小白菊内酯–NO供体杂合物47-54,57a–57b和60对胰腺癌Panc-1细胞的抑制作用
a所有数据均为三次独立测试的平均值，表示方法为平均值±标准偏差；bPanc-1:胰腺癌细胞系从表3可以看出，小白菊内酯–NO供体杂合物47-54,57a–57b和60对胰腺癌Panc-1细胞抑制作用明显。
表4小白菊内酯–NO供体杂合物对胰腺癌Panc-1细胞的抑制作用ab
| 化合物 | IC<sub>50</sub>(μM)<sup>ab</sup> |
| 62a | 0.037±0.017 |
| 62b | 0.058±0.027 |
| 62c | 0.034±0.016 |
| 62d | 0.114±0.019 |
| 65a | 0.128±0.090 |
| 65b | 0.142±0.112 |
| 66 | 0.180±0.110 |
| 67 | 0.048±0.021 |
| 68 | 0.024±0.011 |
| 69 | 0.386±0.203 |
| 70 | 0.118±0.057 |
| 71 | 0.424±0.102 |
| 72c | 0.24±0.06 |
| 72d | 0.22±0.05 |
| 72e | 0.14±0.01 |
| 72f | 0.13±0.02 |
| 72g | 0.13±0.01 |
| 72h | 0.15±0.02 |
| 72i | 0.24±0.03 |
| 74 | 0.19±0.003 |
| PTL | 5.14±0.72 |
| ADR | 0.87±0.09 |
a所有数据均为三次独立测试的平均值，表示方法为平均值±标准偏差。bPanc-1:胰腺癌细胞系。
从表4可以看出，小白菊内酯–NO供体杂合物对胰腺癌Panc-1细胞的抑制作用十分明显。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。
Claims (9)
1.一种如式(Ⅰ)所示的小白菊内酯-苯磺酰基呋咱衍生物，
式(Ⅰ)中X为氧原子或氮原子；
并且R1为如下结构之一：
其中Y所代表的基团，是择一关系；
R2为如下结构之一：
R5可以存在也可以不存在，当R5不存在时，R3、R4共同构成单键；或当R3和R5为氢时，R4为-NR6R7；其中R6和R7可以相同或不同，分别为氢、烷基、环烷基、羟基取代烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基、杂环基、三氟甲基、多氟取代烷基、腈基、腈基甲基、酰基、氨基甲酰基、磺酰基、磺酰胺基或芳氧烷基；R6、R7和N原子形成环状结构。
2.根据权利要求1所述的小白菊内酯-苯磺酰基呋咱衍生物，其特征是，通式如下式(Ⅱ)至(Ⅷ)中的任意一种化合物：
R1:
R2:
3.根据权利要求1或2所述小白菊内酯-苯磺酰基呋咱衍生物，其特征是，R6、R7和N原子形成环状结构为3–9元环，环状结构上可以被一个或多个取代基取代，取代基包括氢、烷基、环烷基、烯基、炔基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基或杂环基。
4.一种权利要求1或2所述小白菊内酯-苯磺酰基呋咱衍生物的盐，其特征是，权利要求1所述小白菊内酯-苯磺酰基呋咱衍生物与无机酸或有机酸形成的在药学上可接受的盐。
5.根据权利要求4所述小白菊内酯-苯磺酰基呋咱衍生物的盐，其特征是，所述无机酸为氢氟酸、盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸、碳酸，硼酸、亚硒酸、磷钼酸、亚磷酸或亚硫酸。
6.根据权利要求4所述小白菊内酯-苯磺酰基呋咱衍生物的盐，其特征是，所述有机酸为柠檬酸、马来酸、D-苹果酸、L-苹果酸、DL-苹果酸、L-乳酸、D-乳酸、DL-乳酸、草酸、甲磺酸、戊酸、油酸、月桂酸、对甲基苯磺酸、1-萘磺酸、2-萘磺酸、酞酸、酒石酸、丙二酸、丁二酸、富马酸、乙醇酸、硫醇酸、甘氨酸、肌氨酸、磺酸、烟酸、甲基吡啶酸、异烟酸、二氯乙酸、苯甲酸或取代苯甲酸。
7.根据权利要求4所述小白菊内酯-苯磺酰基呋咱衍生物的盐，其特征是，包括所述小白菊内酯-苯磺酰基呋咱衍生物与R8Z形成的季铵盐，Z为氟、氯、溴、碘、对甲苯磺酸酯基、甲磺酸酯基、苯磺酸酯基或三氟甲基磺酸酯基；R8为烃基、环烷基、羟基取代烷基、烯基、炔基、芳基、杂环基、芳基取代烷基、芳基烯基、芳基炔基、氰基取代甲基、烷氧基取代烷基或芳氧取代烷基。
8.权利要求1至7任意一项权利要求所述小白菊内酯-苯磺酰基呋咱衍生物或其盐在制备抗癌药物或制备辅助抗癌药物中的用途，其中癌症为白血病、乳腺癌、前列腺癌、鼻咽癌、大肠癌、肺癌、肝癌、食道癌、胃癌、肠道癌、肾癌、口腔癌、何杰金淋巴癌、胰腺癌、直肠结肠癌、子宫颈癌、非何杰金淋巴癌、神经胶质瘤、黑瘤、膀胱癌、卵巢癌、甲状腺癌或卡波西肉瘤。
9.权利要求1至7任意一项权利要求所述小白菊内酯-苯磺酰基呋咱衍生物或其盐与药学上可接受的载体或与其他抗癌药物形成的组合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910491707.XA CN112047953B (zh) | 2019-06-06 | 2019-06-06 | 小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910491707.XA CN112047953B (zh) | 2019-06-06 | 2019-06-06 | 小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112047953A true CN112047953A (zh) | 2020-12-08 |
| CN112047953B CN112047953B (zh) | 2023-12-29 |
Family
ID=73609022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910491707.XA Active CN112047953B (zh) | 2019-06-06 | 2019-06-06 | 小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112047953B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112876495A (zh) * | 2019-11-29 | 2021-06-01 | 中国医学科学院药物研究所 | 小白菊内酯衍生物、其药物组合物及其制备方法和用途 |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078995A1 (en) * | 2005-01-21 | 2006-07-27 | Nitromed, Inc. | Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use |
| WO2008087488A2 (en) * | 2006-10-22 | 2008-07-24 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
| CN101530411A (zh) * | 2009-04-14 | 2009-09-16 | 中国药科大学 | 一种no供体型化合物作为p-糖蛋白抑制剂和肿瘤多药耐药逆转剂的应用 |
| CN101633684A (zh) * | 2008-07-21 | 2010-01-27 | 王志凤 | 新型三萜衍生物及其药物用途 |
| CN101775059A (zh) * | 2010-02-04 | 2010-07-14 | 中国药科大学 | 新的甘草次酸衍生物、其制备方法及其医药用途 |
| CN101812059A (zh) * | 2010-04-14 | 2010-08-25 | 中国药科大学 | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 |
| WO2014008875A1 (de) * | 2012-07-12 | 2014-01-16 | Cardionovum Gmbh | Katheterballon, verfahren zur herstellung eines beschichteten katheterballons sowie verwendung des pharmakologischen wirkstoffs |
| CN103694238A (zh) * | 2014-01-13 | 2014-04-02 | 何黎琴 | No供体型苦参碱衍生物、其制备方法及医药用途 |
| US20150133444A1 (en) * | 2013-11-08 | 2015-05-14 | Venumadhav Janganati | Melampomagnolide b derivatives |
| CN104693257A (zh) * | 2015-02-03 | 2015-06-10 | 南通大学 | 苯磺酰基呋咱修饰的吉西他滨衍生物及其制备方法和用途 |
| CN105622607A (zh) * | 2016-01-12 | 2016-06-01 | 沈阳药科大学 | 一类具有抗肿瘤活性的呋咱类no供体型吴茱萸碱衍生物 |
| CN106928293A (zh) * | 2017-03-10 | 2017-07-07 | 沈阳药科大学 | 一类具有抗肿瘤活性的呋咱no供体型灯盏乙素衍生物及其制备方法和用途 |
| CN110156735A (zh) * | 2019-04-23 | 2019-08-23 | 天津国际生物医药联合研究院 | 芒柄花黄素衍生物及其制备方法和应用 |
| CN111072682A (zh) * | 2019-11-07 | 2020-04-28 | 沈阳药科大学 | 白屈菜碱呋咱类一氧化氮供体衍生物及其制备方法和用途 |
| CN111454275A (zh) * | 2019-01-18 | 2020-07-28 | 洛阳尚德药缘科技有限公司 | 倍半萜内酯—肉桂酸衍生物及其盐，药物组合物及其用途 |
| CN111454274A (zh) * | 2019-01-18 | 2020-07-28 | 洛阳尚德药缘科技有限公司 | 倍半萜内酯—saha衍生物的制备方法及其在制备抗癌药物中的用途 |
| CN112876495A (zh) * | 2019-11-29 | 2021-06-01 | 中国医学科学院药物研究所 | 小白菊内酯衍生物、其药物组合物及其制备方法和用途 |
-
2019
- 2019-06-06 CN CN201910491707.XA patent/CN112047953B/zh active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078995A1 (en) * | 2005-01-21 | 2006-07-27 | Nitromed, Inc. | Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use |
| WO2008087488A2 (en) * | 2006-10-22 | 2008-07-24 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
| CN101633684A (zh) * | 2008-07-21 | 2010-01-27 | 王志凤 | 新型三萜衍生物及其药物用途 |
| CN101530411A (zh) * | 2009-04-14 | 2009-09-16 | 中国药科大学 | 一种no供体型化合物作为p-糖蛋白抑制剂和肿瘤多药耐药逆转剂的应用 |
| CN101775059A (zh) * | 2010-02-04 | 2010-07-14 | 中国药科大学 | 新的甘草次酸衍生物、其制备方法及其医药用途 |
| CN101812059A (zh) * | 2010-04-14 | 2010-08-25 | 中国药科大学 | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 |
| WO2014008875A1 (de) * | 2012-07-12 | 2014-01-16 | Cardionovum Gmbh | Katheterballon, verfahren zur herstellung eines beschichteten katheterballons sowie verwendung des pharmakologischen wirkstoffs |
| US20150133444A1 (en) * | 2013-11-08 | 2015-05-14 | Venumadhav Janganati | Melampomagnolide b derivatives |
| CN103694238A (zh) * | 2014-01-13 | 2014-04-02 | 何黎琴 | No供体型苦参碱衍生物、其制备方法及医药用途 |
| CN104693257A (zh) * | 2015-02-03 | 2015-06-10 | 南通大学 | 苯磺酰基呋咱修饰的吉西他滨衍生物及其制备方法和用途 |
| CN105622607A (zh) * | 2016-01-12 | 2016-06-01 | 沈阳药科大学 | 一类具有抗肿瘤活性的呋咱类no供体型吴茱萸碱衍生物 |
| CN106928293A (zh) * | 2017-03-10 | 2017-07-07 | 沈阳药科大学 | 一类具有抗肿瘤活性的呋咱no供体型灯盏乙素衍生物及其制备方法和用途 |
| CN111454275A (zh) * | 2019-01-18 | 2020-07-28 | 洛阳尚德药缘科技有限公司 | 倍半萜内酯—肉桂酸衍生物及其盐，药物组合物及其用途 |
| CN111454274A (zh) * | 2019-01-18 | 2020-07-28 | 洛阳尚德药缘科技有限公司 | 倍半萜内酯—saha衍生物的制备方法及其在制备抗癌药物中的用途 |
| CN110156735A (zh) * | 2019-04-23 | 2019-08-23 | 天津国际生物医药联合研究院 | 芒柄花黄素衍生物及其制备方法和应用 |
| CN111072682A (zh) * | 2019-11-07 | 2020-04-28 | 沈阳药科大学 | 白屈菜碱呋咱类一氧化氮供体衍生物及其制备方法和用途 |
| CN112876495A (zh) * | 2019-11-29 | 2021-06-01 | 中国医学科学院药物研究所 | 小白菊内酯衍生物、其药物组合物及其制备方法和用途 |
Non-Patent Citations (9)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112876495A (zh) * | 2019-11-29 | 2021-06-01 | 中国医学科学院药物研究所 | 小白菊内酯衍生物、其药物组合物及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112047953B (zh) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2870006T3 (es) | Procedimiento para producir compuestos que tienen actividad inhibidora de la integrasa del HIV | |
| JP7548814B2 (ja) | Ｉｄｏ阻害剤および／またはｉｄｏ－ｈｄａｃ二重阻害剤としての多環式化合物 | |
| ES2655028T3 (es) | Proceso para la síntesis de inhibidores de enzima de activación de E1 | |
| CN113286794A (zh) | Kras突变蛋白抑制剂 | |
| NO329020B1 (no) | Difluorpyridiner | |
| TW200946531A (en) | HSP90 inhibitors | |
| CN109180681B (zh) | 一种dna毒性二聚体化合物 | |
| CN109575013A (zh) | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 | |
| JP5762624B2 (ja) | 安定な７員環ラクトンを含むカンプトテシン化合物、それらの製造方法及び使用 | |
| CN112047953A (zh) | 小白菊内酯-苯磺酰基呋咱衍生物及其盐，制备方法和应用 | |
| PT89775B (pt) | Processo para a preparacao de derivados de isoquinolina | |
| CN112175037B (zh) | 常春藤皂苷元聚乙二醇衍生物及其制备方法 | |
| WO2013132262A1 (en) | Picropodophyllin derivatives | |
| CN108948003B (zh) | 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途 | |
| CN115515958B (zh) | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 | |
| CN104395312A (zh) | 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用 | |
| CN114213501B (zh) | A环并异噁唑环常春藤皂苷元c-23位含氮杂环衍生物及其制备方法 | |
| JPH04187686A (ja) | インドロカルバゾール誘導体 | |
| CN109575051B (zh) | 一种天然药物成分修饰衍生物及其抗肿瘤应用 | |
| CN111247143A (zh) | 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物 | |
| CN111825631B (zh) | Be-43547衍生物及其盐，制备方法及其在制备抗癌药物中的用途 | |
| CN114191439A (zh) | A环并异噁唑环常春藤皂苷元c-23位含氮杂环衍生物的应用 | |
| JPH04145085A (ja) | スタウロスポリンのγ―ラクタム環誘導体とそのアンモニウム塩 | |
| JP2022517621A (ja) | ホステムサビルの調製方法 | |
| Goel | Synthesis of Novel Tröger’s Base-Derived Helical Scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |